

International Scientific Advisory Committee, 5th ISSX Meeting, 1998

International Advisory Committee, 12th International Symposium on Microsomes and Drug Oxidations, 1998

NIH Senior Biomedical Research Service Policy Board, 1996-present

NIH Central Tenure Committee, 1997-present

Ad hoc Member, Metabolism Study Section, NIH, August, 1997

Science Advisory Committee, Chemical Industry Institute of Toxicology, 1997-present

NIAAA Search Committee for a tenure tract investigator, 1998

NCI-DBS Search Committee for a tenure tract developmental biologist, 1998

International Advisory and Scientific Committee, 4th Congress of Toxicology in Developing Countries, 1999

International Advisory Committee, 13th International Symposium on Microsomes and Drug Oxidations, 2000

International Advisory Committee, 12th International Conference on Biochemistry and Molecular Biology of Cytochrome P450, 2001

Comparative Medicine Emphasis Panel, National Center for Research Resources, NIH, July 1999

Consulting Activities:

Astra Hassle
Dupont-Merck Pharmaceuticals
Glaxo Research Group
Hoffman-La Roche Inc.
Merck & Co. Ltd.
Monsanto Chemical Co.
Pfizer Inc.
Rhone-Poulenc (France)
Rhone-Poulenc Rorer (U S.)

Awards and Other Special Scientific Recognition

Merit Award, National Institutes of Health, October, 1990

Rawls-Palmer Progress in Medicine Award, American Society for Clinical Pharmacology and Therapeutics, 1991

John J. Abel Award in Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 1992

Honorary Lectureship of the National Science Council, Republic of China, Taiwan, 1993

Federal Technology Transfer Award, National Institutes of Health, 1994

George Scott Award, Toxicology Forum, 1995

Visiting Professor Travel Award, Japanese Ministry of Science and Education, 1995

Member, Senior Biomedical Research Service, 1996-

Honorary Visiting Professor, Mahidol University, Bangkok Thailand, 1997

Japanese Society for the Promotion of Science (JSPS) short term fellowship, 1998

Technology Transfer Award, National Cancer Institute, 1999

Keynote, special and plenary lectures, (see below)

Patents:

Methods for identifying humans with genetic defects in drug metabolism P450. # 5,164,313, issued November 17, 1992

Recombinant vaccinia virus encoding cytochromes. # 5,506,138 issued April 16, 1996

Immortalized human cell lines containing exogenous cytochrome P450 genes. # 5,506,131, issued April 9, 1996

Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene, # 5,726,041, issued March 10, 1998

cDNA for human and pig dihydropyrimidine dehydrogenase # 5,865,454, issued January 5, 1999.

Defects in drug metabolism, # 5,891,633, issued April 6, 1999

Inhibitory and non-inhibitory antigen binding polypeptides against human P450 enzymes, # 5,939,530, issued August 17, 1999.

Invited Lectures (Selected list, 1985-Date and Projected).

- 1985: First Cytochrome P-450 Gene Workshop, Airlie Virginia, April
American Society of Pharmacology and Experimental Therapeutics, Boston
Massachusetts, May
Department of Pharmacology and Therapeutics, University of Florida, Gainesville
Florida, September
- 1986: Department of Biochemistry, New Jersey Medical School, Newark New Jersey
Fifty First Cold Spring Harbor Symposium, Cold Spring Harbor New York, June
(Declined)
Department of Biochemistry, Georgetown University, Washington D.C
- 1987: Second Cytochrome P-450 Gene Workshop, Airlie Virginia, April
Human Collaborative Studies Meeting, Rockville Maryland, May
St. Jude Children's Research Hospital, Memphis Tennessee, May
Symposium, American Association of Cancer Research, Atlanta Georgia, May
Symposium, American Association of Pharmaceutical Scientists, Boston
Massachusetts, June
Seventh International Symposium on Microsomes and Drug Oxidations, Adelaide
Australia, August
- 1988: Workshop, Cellular and Molecular Aspects of Glucuronidation, Montpellier
France, April (Declined)
Department of Oncology, McArdle Laboratory for Cancer Research, Madison
Wisconsin, April
Second International ISSX Meeting on Xenobiotic Metabolism and Disposition,
Kobe Japan, May
Symposium on Drug Metabolism in honor of Dr. Gilbert Mannering, University of
Minnesota, Minneapolis Minnesota, June
Sixth International Congress on Biochemistry and Biophysics of Cytochrome P-
450, Vienna Austria, July
Department of Biochemistry, University of Texas, Dallas Texas, September
Symposium on Mechanism-based Inactivation of Oxidative Enzymes at the
American Association of Pharmaceutical Sciences Meeting, Orlando Florida,
October
Department of Biochemistry, Mount Sinai School of Medicine, New York, October

Symposium on Specificity and Molecular Biology of Cytochromes P450, Central Research Laboratories, Monsanto Company, St Louis Missouri, October

Department of Environmental Toxicology, University of Cincinnati, Cincinnati Ohio, November

Integrated Genetics, Framingham Massachusetts, November

1989: U.S.-Japan Cooperative Cancer Research Program: Cytochrome P450 and Carcinogenesis, Honolulu, January

Symposium, Society of Toxicology, Atlanta Georgia, February

Third Workshop on the Regulation of Genes that are Influenced by the Environment, Airlie Virginia, May

Twenty-eighth Annual International Industrial Pharmacy Conference Management and Regulation of New Technology, Austin Texas, June

Gordon Conference on Drug Metabolism, New Hampshire, July

Symposium, Fifth International Conference on Environmental Mutagens, Cleveland Ohio, July.

Workshop on The Molecular Approaches to Drug Abuse Research, sponsored by The National Institutes on Drug Abuse, Bethesda Maryland, August.

Symposium on Genetic Susceptibility to Environmental Agents, Edinburgh Scotland, September

Department of Pharmacology, Cornell University, Ithaca New York, November

Keynote Speaker, Symposium on Application of Advanced Techniques for Assessment of Human Toxicity sponsored by the Genetic and Environmental Toxicology Association, San Francisco California, December

1990: Department of Clinical Pharmacology, Vanderbilt University, Nashville, February

Department of Pharmacology, George Washington University, Washington D.C., February

Department of Pharmacology, University of Virginia, Charlottesville, March

Department of Pharmacology, University of Washington, Seattle, March

Session Chairperson, NCI-NIOSH sponsored workshop on the use of biological markers in occupational epidemiologic investigations of cancer, Williamsburg, May.

Symposium, American Society of Biochemistry and Molecular Biology, New Orleans, June

Fifth Congress of the International Society for Biomedical Research on Alcoholism, Toronto, June

Keynote Speaker, Eighth International Symposium on Microsomes and Drug Oxidations, Stockholm, June

Visiting Professor, Gulbenkian Advanced Course on Liver Specific Gene Expression and Signaling Pathways Controlling Cell Growth, Gulbenkian Institute of Science, Lisbon, September

Falk Symposium No. 57: Hepatic Metabolism and Disposition of Endo- and Xenobiotics, Freiburg Germany, October

International Symposium on Trends in Biological Dosimetry, Lercı Italy, October

Princess Takamatsu Cancer Research Fund, 21st International Symposium, Tokyo, November

1991: Department of Biochemistry, Bowman-Grey School of Medicine, Wake Forest University, Winston-Salem South Carolina, February

Department of Chemical Biology and Pharmacognosy, Rutgers University School of Pharmacy, Piscataway New Jersey, February

Rawls-Palmer Progress in Medicine Award lecture, American Society for Clinical Pharmacology and Therapeutics, San Antonio, March

American Cancer Society's 33rd Annual Science Writers Seminar, Phoenix, March

Symposium, Environmental Mutagen Society, Orlando, April

Symposium, Federation of the American Societies for Experimental Biology, Atlanta, April

Department of Clinical Pharmacology, Georgetown University Medical School, Washington D.C., April

International Conference on Environmental Mutagens, Shanghai, May
(Declined)

Gordon Conference on Genetic Toxicology, New London New Hampshire, June

Institute of Biosciences and Technology and Texas A&M University, Houston, June

Symposium entitled "Application of Cellular Systems in Drug Metabolism and Toxicity Studies", Otzenhausen Germany, July

Seventh International Conference on Biochemistry and Biophysics of Cytochrome P-450: Structure, Function, Biotechnological and Biological Aspects, Moscow, July

Biomonitoring Symposium, American Chemical Society, New York, August

Department of Molecular Pharmacology, Albert Einstein University, New York, September

Ares-Serono Symposium entitled "A Molecular View of Steroid Biosynthesis and Metabolism", Jerusalem, October (Declined, Dr. Korzekwa will present)

Symposium, Applications of Molecular Biology to Toxicology and Pathology, Pharmaceutical Manufacturers Association, New Orleans, October

Symposium on Cell Culture Systems to Evaluate Human Risk to Chemical Exposure, Glaxo Inc. Research Institute, Research Triangle Park, October.

Symposium entitled "Biomonitoring and Susceptibility Markers in Human Cancer: Applications in Molecular Epidemiology and Risk Assessment", Kona Hawaii, October

Sendai International Symposium entitled "Recent Advances in Cancer Research", Sendai Japan, November

Grand Rounds, National Institutes of Health, December

1992: Department of Pharmacology, Uniformed Services University of Health Science, Bethesda, January

Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, February

Department of Cell Biology, New York University, New York, March

University of Chicago Cancer Research Center, Chicago, March

American Cancer Society's 34th Annual Science Writers Seminar, St. Petersburg Florida, March

Department of Physiology, Case Western Reserve, Cleveland Ohio, April

Graduate Student Symposium entitled "Evolution From the Inside: The Influence of Cellular and Developmental Processes in Evolution", University of Colorado, Boulder, April

1st International Union of Biochemistry and Molecular Biology Conference: Biochemistry of Disease, Nagoya Japan, June

Canadian Federation of Biological Societies, Victoria, British Columbia, Canada, June

Session Chairman and Speaker, International Conference on Monitoring Toxic Chemicals and Biomarkers, Berlin, June

Session Chairman and Speaker 9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, July

Gordon Conference on Drug Metabolism, New Hampshire, July.

Special Lecture, Vth World Congress on Clinical Pharmacology and Therapeutics, Yokohama Japan, July

Division of Clinical Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, September

Third Annual Schweppe Colloquium on Mechanisms of Carcinogenesis, Northwestern University, Chicago Illinois, September

International Symposium on Environmental Skin Cancer Mechanisms, Models and Human Relevance, Cleveland Ohio, October

Special Lecture, Pharmaceutical Society of Korea, Seoul, October

Keynote presentation, The Thirty-First Hanford Symposium on Health and the Environment on "The Laboratory and Epidemiology", Richland, Washington, October.

Symposium, American Association for the Study of Liver Disease, Chicago, October

Arkansas Toxicology Symposium entitled "Concepts and Techniques in Chemical Carcinogenesis" Little Rock Arkansas, December

1993: Special Honorary Lecture in association with Martin Luther King Day activities, University of Michigan Medical School, Ann Arbor, January

Forum on Drug Development Workshop, Washington D.C., January (declined)

Gordon Conference on Agricultural Sciences, Oxnard California, January

Session Chairman and Speaker, Sixth International Conference on Environmental Mutagens, Melbourne Australia, February

U.S.-Japan joint Cancer Research Meeting, Maui Hawaii, March

First Distinguished Lecture, Center for Environmental Genetics, University of Cincinnati, Cincinnati, April

Keynote address, Joint U.K./Scottish & Newcastle Drug Metabolism Group Meeting, Newcastle England, April

ALZA 25th Anniversary Symposium, Genetic Diversity and Pharmacologic Implication, Palo Alto California, June

Gordon Conference on Drug Metabolism, Plymouth New Hampshire, July

Eighth Aspen Cancer Conference: Molecular mechanism of toxicity in relation to the genetics of animal and human neoplasia, Aspen, July

Plenary lecture, Fifth European ISSX Meeting, Tours France, September

Colloquium on "Human cytochromes P450 as new tools in drug design and development", Paris, October

9th International Conference on Biochemistry, Biophysics and Molecular Biology of Cytochrome P450, Lisbon, October

Pharmacogenetics workshop, National Cheng Kung University Medical Center, Tainan Taiwan, December

Academic Sinica, Taipei Taiwan, December

1994: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, January

US-Japan joint workshop on Roles of genetic polymorphism of drug metabolism on cancer susceptibility, Kauai Hawaii, February

Keynote lecture, Workshop on the "Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research", Berlin, March

Organizer, Chairman and Speaker, Symposium on Pharmacogenetics: Role of Polymorphisms in Drug Metabolism on Cancer Chemotherapy. 85th Annual Meeting of the American Association for Cancer Research, San Francisco, April

Workshop on Biomarkers sponsored by the Department of Energy, Santa Fe, April

Southeast Regional AAPS Meeting Symposium entitled "Can In Vitro Models Predict In Vivo Drug Metabolism", Durham North Carolina, April

ASBMB and ISSX joint symposium on The Cytochromes P450: Structure, Function, Regulation, and Genetics, Washington D C., May

Genetic Toxicology Association, Wilmington Delaware, June

Special Lecture, Mexican National Academy of Medicine Annual Meeting, Mexico City, June

14th International Symposium on Cancer, Sapporo Cancer Seminar on Genetic Polymorphism and Cancer Susceptibility, Sapporo Japan, July

10th International Symposium on Microsomes and Drug Oxidations, Toronto Canada, July

Pacific Rim Association for Clinical Pharmacogenetics, Toronto, July

International Union of Pharmacology, Montreal Canada, August

Flavor Extract Manufacturers' Association of the United States, Washington D.C., September

Symposium entitled "Molecular Mechanisms of Environmental Carcinogenesis", NIEHS, Research Triangle Park, September

Sixth North American ISSX Meeting, Research Triangle Park, October

Keynote lecture, 7th Southeast Asia Drug Metabolism Workshop, Bangkok, November

- ACNP symposium on Importance of Cytochrome P450 Chemistry in Psychopharmacology, San Juan Puerto Rico, December
1995. Keystone symposium on Molecular Toxicology, Copper Mountain Colorado, January
- US-Japan joint workshop on Complex Mixtures, Maui Hawaii, March
- Symposium entitled "Mechanistic basis for ethnic differences in cancer risk", 86th meeting of the American Association for Cancer Research, Toronto, March
- New York State Department of Health, Albany, April
- Organizer and Chairman, Conference on Pharmacogenetics, sponsored by International Business Communications, Bethesda, May
- Symposium on Pathology of Induced Mutants, San Diego, June
- International symposium on Strategy of Drug Metabolism for Study of New Drug Development, Tokyo, June
- Session Chair, International Symposium on Peroxisomes: Biology and Role in Toxicology and Disease, Aspen, June
- 9th International symposium on Cytochrome P450 Biochemistry and Biophysics, Zurich, July
- International Congress of Toxicology, Seattle, July
- 5th International ISSX meeting, Seattle, August
- 7th International CBT Symposium on Nuclear Orphan Receptors: Novel Regulators in Physiology and Pathology, Huddinge Sweden, September
- Visiting Lectureship, Japan Ministry of Science and Education, Nine lectures on four topics, Japan, October
- Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, Ioannina Greece, October
- US-Japan joint workshop on Transgenic Animals and Carcinogenesis, Kauai Hawaii, November.
- National Research Council Symposium entitled New Approaches for Assessing the Etiology and Risks of Development Abnormalities from Chemical Exposure, Washington D.C., December
- Workshop on Peroxisome Proliferation sponsored by the ILSI Health and Environmental Sciences Institute, Virginia, December
- 1996: American Association for Cancer Research special conference on "Cancer Susceptibility Genes and Molecular Carcinogenesis", Keystone, February

IBC Conference on Molecular Toxicology, Orlando, February

American Society for Clinical Pharmacology and Therapeutics Workshop on Hematologic and Neoplastic Diseases, Orlando, March

Vanderbilt University's Molecular Toxicology Center's seminar series, Nashville, March

American Association for Cancer Research annual meeting symposium entitled "Drug Metabolizing Enzymes in Cancer Prevention and Therapy", Washington D C., April

John Doull Toxicology Symposium, University of Kansas Medical Center, Kansas City Kansas, May

The Peter Dresel Memorial Lecture, Dalhousie University, Halifax Nova Scotia, May

Society of Pediatric Research/Academic Pediatric Society joint meeting, Washington D.C., May

IBC International Pharmacogenetics Conference, Washington D.C , May

American Association for Cancer Research Special Conference on "Inducible Genomic Responses", Stevenson WA, June

Joint meeting of the Research Society on Alcoholism and International Society for Biomedical Research on Alcoholism, Washington DC, June

Gordon Research Conference on Drug Metabolism, Plymouth, July

Sixth Stowe Symposium on Drug Metabolism, United Kingdom, July

11th International Symposium on Microsomes and Drug Oxidation, Los Angeles, July

Special lecture, 23rd Meeting of The Japanese Society of Toxicological Sciences, Fukuoka Japan, July

Workshop on "Pharmacogenetics at the Molecular Level", 9th International Congress of Human Genetics, Rio de Janeiro, August

American Institute for Cancer Research conference entitled Dietary Fat and Cancer: Genetic and Molecular Interactions, Washington D.C. August

French Biochemical and Molecular Biology Society Symposium on "PPARs, Nutriment and Xenobiotics as Mediators of Cell Regulation", Dijon France, September

Special lecture, 11th Annual Meeting of the Japanese Society for the Study of Xenobiotics, Kanazawa Japan, October

Italian In Vitro Toxicology Association symposium entitled "Genetically Manipulated Systems in Toxicology", St. Margherita Italy, December.

- 1997: British Society of Toxicology Annual Congress, Warwick, March
- Society of Toxicology Annual Meeting, Cincinnati, March
- ASPET Symposium on Polymorphisms of Drug Metabolizing Enzymes, San Diego, March
- U S Japan Joint Workshop on Genetic and Environmental Interactions in Cancer Susceptibility in Animal Models, Bethesda, March
- Biomarkers, the Genome and the Individual: Workplace and Medical Implications of a Rapidly Evolving Technology, Hilton Head SC, May (declined)
- EC/US Workshop on "The Integration of Multi-endpoint Mechanistic Information in Risk Assessment", Ispra Italy, May (declined)
- Twenty ninth Nobel Conference on "Metabolic Functions, Proliferation and Diseases of Peroxisomes", Stockholm, June
- 6th European ISSX Meeting, Gothenburg Sweden, June
- 12th Aspen Cancer Conference, Aspen, July
- NATO Advanced Study Institute Course on "Molecular and Applied Aspects of Oxidative Drug Metabolizing Enzymes", Antalya Turkey, August
- Keynote lecture, 2nd European Association for Clinical Pharmacology and Therapeutics, Berlin, September
- Symposium in honor of Professor Alfred G. Hildebrandt on "Microsomes, Drug Oxidation and Clinical Pharmacology", Berlin, September
- North American International Society for the Study of Xenobiotics (ISSX) Conference, Hilton Head SC, October
- Annual Meeting of the American College of Clinical Pharmacy, Phoenix, November
- 9th International CBT Symposium on Nuclear Steroid and Orphan Receptors, Huddinge Sweden, October
- Boston University, Department of Biology, December
- 1998: American Association of Pharmaceutical Scientists meeting First AAPS Frontier Symposium entitled "From Good Ligands to Good Drugs: Optimizing Pharmaceutical Properties by Accelerated Screening", Bethesda, February
- ASPET Symposium on "Physiological and Pathophysiological Regulation of Cytochrome P450", San Francisco, April
- ASPET Symposium in honor Anthony Lu's retirement, San Francisco, April
- British Toxicology Society, Surrey, April (declined)

British Pharmacological Society, Gullford, April

Keynote address, Visions in Pharmacology Research Day, University of Toronto, May, Toronto

The Endocrine Society Annual Meeting, June, New Orleans

Third IBC Conference on Molecular Toxicology, May, Washington D.C.
(declined)

Seventh International Bioinformatics and Genome Research Conference, Boston
June (declined)

Symposium on Hepatic and Intestinal Defense Mechanisms, June, Gottingen
Germany (declined)

8th International Congress of Toxicology, July, Paris

Plenary lecture, 12th International Symposium on Microsomes and Drug
Oxidations, Montpellier France, July

Plenary lecture, XIIIth International Union of Pharmacology World Congress,
Munich, July

Rodent Models in Modern Risk Assessment Workshop, The Jackson Laboratory,
Bar Harbor Maine, September

University of Wisconsin Land of Lakes Conference on Drug Metabolism,
Merrimac, WI, September (declined)

Keynote speaker, University of California at Davis Molecular Biosciences Graduate
Student Symposium, Davis CA, October

Keynote lecture, German Society of Pharmacology and Toxicology, Hannover
Germany, October (declined)

5th International International Society for the Study of Xenobiotics (ISSX)
Meeting, Cairns Australia, October

7th International Conference on Carcinogenic/Mutagenic N-Substituted Aryl
Compounds, Nagoya Japan, November

Special lecture, Japanese Society for the Study of Xenobiotics, Sendai Japan,
November

Symposium entitled "Transgenic Animals in Drug Development: Scientific and
Regulatory Perspectives" co-sponsored by the Institute for Scientific Exchange and
the International Association for Regulatory Toxicologists and Pharmacologists,
Baltimore, December

1999: The Third Williams Lecture, Department of Pharmacology and Toxicology,
University of South Florida, March

Plenary Lecture, 30th Environmental Mutagen Society, Washington DC, March

Millennial World Congress of Pharmaceutical Sciences, San Francisco, April
(declined)

Keynote speaker, 7th Pacific Rim Association for Clinical Pharmacogenetics, April,
Taiwan

Keystone Symposium on "The PPARs Transcriptional Links to Obesity, Diabetes,
and Cardiovascular Disease", Keystone, April

Department of Biopharmaceutical Sciences, the Human Genetics Program, UCSF
Cancer Center, May (declined)

International Federation of Clinical Chemistry and Laboratory Medicine, Florence
Italy, June

11th International Conference on Cytochrome P450 Biochemistry, Biophysics and
Molecular Biology, Sendai Japan, August

Keynote speaker, Mountain West Society of Toxicology Meeting, Breckenridge CO,
September

International Symposium, sponsored by the Fujihara Foundation of Science,
entitled "Analysis and prevention of carcinogenesis in animal models modulated
with DNA repair related genes", September

Center for Biologics, FDA sponsored workshop on plasticizers, October

The University of Texas Southwestern Medical Center, Department of
Pharmacology, November

European Council for Plasticizers and Intermediates meeting on "Risk assessment
of peroxisome proliferators", Brussels, November

2000: The XII Congress of Italian Society of Toxicology, Bologna Italy, February

2000 International Fuller Symposium on "Insulin Resistance in Hypertension
Pathobiology and Therapeutics", London Ontario, March

ASPET Symposium in the aryl hydrocarbon receptor, Boston, June

International workshop entitled "From Sequence to Function: Experimental and
Bioinformatic Studies of Cytochrome P450 Superfamily", Moscow, July

13th International Symposium on Microsomes and Drug Oxidations, Stresa Italy,
July

Year 2000 Great Unknowns in Experimental Biology symposium, Comparative
Experimental Biology Societies Year 2000 Congress, Cambridge, August
(declined)

Eurotox 2000, London, September

International Symposium on Predictive Oncology and Therapy, November, Vienna
2001. The Alfred Benzon Foundation Symposium on Drug Metabolism Regulation and
Importance, Copenhagen, September.

Bibliography:

1. Gonzalez, F.J., Garrett, C.T., Wiener, D., and Caine, M.D. · The use of potassium iodide equilibrium density gradient centrifugation in the purification of RNA for hybridization with nonreiterated DNA sequences Anal Biochem 85: 146-156, 1978.
2. Garrett C.T., Gonzalez, F.J., Caine, M., Kilner, J., Wiener, D., and Genta, V.M.: Expression of nonreiterated sequence transcripts in transplantable hepatomas and regenerating rat liver. Vestn Akad Med Nauk USSR, 6:40-45, 1980.
3. Gonzalez, F.J., and Kasper, C.B. · Phenobarbital induction of NADPH-cytochrome c (P-450) oxidoreductase messenger ribonucleic acid. Biochemistry 19: 1790-1796, 1980.
4. Gonzalez, F.J., and Kasper, C.B. In vitro translation of epoxide hydrolase mRNA. Biochem Biophys Res Commun 93: 1254-1258, 1980.
5. Gonzalez, F.J., and Kasper, C.B.: Sequential translocation of two phenobarbital-induced polysomal messenger ribonucleic acids from the nuclear envelope to the endoplasmic reticulum Biochemistry 20: 2292-2298, 1981.
6. Gonzalez, F.J., and Kasper, C.B. : Cloning of epoxide hydratase complementary DNA. J Biol Chem 256: 4697-4700, 1981.
7. Kasper, C.B., and Gonzalez, F.J.. The role of the nuclear envelope in the metabolism of chemical carcinogens. In: E Reid, G. Cool, and D.J. Moore (Eds.), Cancer Cell Organelles, 1982, pp. 202-214.
8. Gonzalez, F.J., and Kasper, C.B.: Differential inducibility of nuclear envelope epoxide hydratase by trans-stilbene oxide and phenobarbital. Mol Pharmacol 21: 511-516, 1982.
9. Gonzalez, F.J., and Kasper, C.B.: Cloning of DNA complementary to rat liver NADPH-cytochrome c (P-450) oxidoreductase and cytochrome P-450b mRNAs. J Biol Chem 257: 5962-5968, 1982.
10. Himeno, M., Mueckler, M.M., Gonzalez, F.J., and Pitot, H.C. · Cloning of DNA complementary to rat liver ornithine amino transferase mRNA J Biol Chem 257: 4669-4672, 1982.
11. Gonzalez, F.J., Samore, M., McQuiddy, P., and Kasper, C.B. · Effects of 2-acetylaminofluorene and N-hydroxy-2-acetylaminofluorene on the cellular levels of epoxide hydratase, cytochrome P-450b, and NADPH-cytochrome P-450 oxidoreductase messenger ribonucleic acids. J Biol Chem 257: 11023-11036, 1982.
12. Gonzalez, F.J., and Kasper, C.B.: Cloning and characterization of the NADPH-cytochrome P-450 oxidoreductase gene. J Biol Chem 258: 1363-1368, 1983.
13. Hardwick, J.P., Gonzalez, F.J., and Kasper, C.B.: Transcriptional regulation of rat liver epoxide hydratase, NADPH-cytochrome P-450 oxidoreductase, and

- cytochrome P-450b genes by phenobarbital J Biol Chem 258. 8081-8085, 1983.
14. Hardwick, J P , Gonzalez, F.J., and Kasper, C B Cloning of DNA complementary to cytochrome P-450 induced by pregnenolone 16-carbonitrile: characterization of its mRNA, gene, and induction response. J Biol Chem 258. 10182-10186, 1983.
 15. Kimura, S., Gonzalez, F.J., and Nebert, D W . Mouse cytochrome P₃-450 cDNA sequence and the complete amino acid sequence Nucleic Acids Res 12. 2917-2927, 1984.
 16. Mackenzie, P I., Gonzalez, F J , and Owens, I.S · UDP glucuronosyltransferase II. Cell free translation of mouse liver mRNA coding for two forms of UDP glucuronosyltransferase. Arch Biochem Biophys. 230. 676-680, 1984.
 17. Gonzalez, F.J., Tukey, R.H., and Nebert, D W.: Structural gene products of the Ah locus. transcriptional regulation of cytochrome P₁-450 and P₃-450 mRNA levels by 3-methylcholanthrene Mol Pharmacol 26. 117-121, 1984.
 18. Gonzalez, F J., Mackenzie, P.I., Kimura, S., and Nebert, D W.: Isolation and characterization of full-length cDNA clones and genomic clones of mouse 3-methylcholanthrene-inducible cytochrome P₁-450 and P₃-450. Gene 29: 281-292, 1984.
 19. Mackenzie, P I., Gonzalez, F J., and Owens, I.S.: Cloning and characterization of DNA complementary to rat liver UDP glucuronosyltransferase mRNA. J Biol Chem. 259: 12153-12160, 1984.
 20. Kimura, S , Gonzalez, F.J., and Nebert, D W.: The murine Ah locus: comparison of the complete cytochrome P₁-450 and P₃-450 cDNA nucleotide and amino acid sequences. J Biol. Chem 259: 10705-10713, 1984.
 21. Nebert, D.W., Kimura, S., and Gonzalez, F.J.: Cytochrome P-450 genes and their regulation. In: E.H. Davidson, and R.A. Firtel (Eds.), Molecular Biology of Development, Alan R. Liss, Inc., New York, 1984, pp. 309-329.
 22. Nebert, D.W., Kimura, S., and Gonzalez, F.J.: Molecular mechanisms of P-450 gene expression following exposure to foreign drugs and carcinogens. In A. Boobis, J. Caldwell, and D. Davies (Eds.), Microsomes and Drug Oxidations, Taylor and Francis Ltd., London, England, 1984, pp. 145-156.
 23. Gonzalez, F J., Kimura, S., and Nebert, D.W.: Comparison of the flanking regions and introns of the mouse 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible cytochrome P₁-450 and P₃-450 genes. J Biol. Chem. 260: 5040-5049, 1985.
 24. Hildebrand, C.E., Stallings, R.L., Gonzalez, F.J., and Nebert, D.W.: Assignment of one cytochrome P-450 gene family to Chinese hamster chromosome 4. Somat Cell Mol. Genet. 11: 391-395, 1985.
 25. Hildebrand, D.E., Gonzalez, F.J., McBride, O.W., and Nebert, D.W.: Assignment of the human 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible cytochrome P₁-450 gene to chromosome 15. Nucleic Acids Res 13: 2009-2016, 1985.

26. Jaiswal, A.K., Gonzalez, F.J., and Nebert, S.W.: Human P₁-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids Res 13: 4503-4520, 1985.
27. Hildebrand, C.E., Gonzalez, F.J., Kozak, C.A., and Nebert, D.W.: Regional linkage analysis of the dioxin-inducible P-450 gene family on mouse chromosome 9. Biochem Biophys Res Commun 130: 396-406, 1985.
28. Jaiswal, A.K., Gonzalez, F.J., and Nebert, D.W.: Human dioxin-inducible cytochrome P₁-450: complementary DNA and amino acid sequence. Science 228: 80-83, 1985.
29. Nebert, D.W., and Gonzalez, F.J.: Cytochrome P-450 gene expression and regulation. Trends Pharmacol Sci 6: 160-164, 1985.
30. Gonzalez, F.J., Nebert, D.W., Hardwick, J.P., and Kasper, C.B.: Complete cDNA and protein sequence of a pregnenolone 16 α -carbonitrile-induced cytochrome P-450: a representative of a new gene family. J Biol Chem 260: 7435-7441, 1985.
31. Tuteja, N., Gonzalez, F.J., and Nebert, D.W.: Developmental and tissue-specific differential regulation of the mouse dioxin-inducible P₁-450 and P₃-450 genes. Dev Biol 112: 184-227, 1985.
32. Peterson, T.C., Gonzalez, F.J., and Nebert, D.W.: Methylation differences in the murine P₁-450 and P₃-450 genes in wild-type and mutant hepatoma cell cultures. Biochem Pharmacol 35: 718-720, 1986.
33. Gonzalez, F.J., and Nebert, D.W.: Autoregulation and upstream positive and negative control regions associated with transcriptional activation of the mouse P₁-450 gene. Nucleic Acids Res 13: 7269-7288, 1985.
34. Tuteja, N., Gonzalez, F.J., and Nebert, D.W.: An example of P-450 catalytic activities not correlated with P-450 mRNA concentrations. Biochem Pharmacol 35: 1718-1720, 1986.
35. Kimura, S., Gonzalez, F.J., and Nebert, D.W.: Tissue-specific expression of the mouse dioxin-inducible P₁450 and P₃450 genes: differential transcriptional activation and mRNA stability in liver and extrahepatic tissues. Mol. Cell. Biol. 6: 1471-1477, 1986.
36. Neuhold, L.A., Gonzalez, F.J., Jaiswal, A.K., and Nebert, D.W.: Dioxin-inducible enhancer region upstream from the mouse P₁450 gene and interaction with a heterologous SV40 promoter. DNA 5: 403-411, 1986.
37. Jaiswal, A.K., Nebert, D.W., and Gonzalez, F.J.: Human P₃450: cDNA and complete amino acid sequence. Nucleic Acids Res, 14: 6773-6774, 1986.
38. Landsman, D.L., Soares, N., Gonzalez, F.J., and Bustin, M.: Chromosomal protein HMG-17: complete human cDNA sequence and evidence for a multi-gene family. J Biol Chem. 261: 800-810, 1986.

39. Gonzalez, F J , Song, B -J , and Hardwick, J P . Pregnenolone 16 α -carbonitrile-inducible P-450 gene family: gene conversion and differential regulation. Mol Cell Biol 6. 2969-2976, 1986.
40. Gonzalez, F.J., Kimura, S., Song, B J., Pastewka, J , Gelboin, H.V., and Hardwick, J P.: Sequence of two related P-450 mRNAs transcriptionally increased during rat development J Biol Chem 261. 10667-10672, 1986.
41. Song, B J., Gelboin, H.V., Park, S.S , Yang, C.S , and Gonzalez, F J : Complementary DNA and protein sequences of ethanol-inducible rat and human P-450: transcriptional and post-transcriptional regulation of the rat enzyme. J Biol Chem 261. 16689-16697, 1986.
42. Nagata, K., Matsunaga, T., Gillette, J., Gelboin, H V., and Gonzalez, F.J. Rat testosterone 7 α -hydroxylase: isolation, sequence, and expression of cDNA and its developmental regulation and induction by 3-methylcholanthrene J Biol Chem 262: 2787-2793, 1987.
43. Hardwick, J.P., Song, B J., Huberman, E., and Gonzalez, F J.: Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid-Hydroxylase (Cytochrome P-450_{LA}): identification of a new cytochrome P-450 gene family. J Biol Chem 262: 801-810, 1987.
44. Gonzalez, F.J., Matsunaga, T., Nagata, K , Meyer, U.A., Nebert, D.W., Pastewka, J., Kozak, C.A., Gillette, J.J., Gelboin, H.V., and Hardwick, J.P.: Debrisoquine 4-hydroxylase: characterization of a new P-450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 6: 149-160, 1987.
45. Jaiswal, A.K., Nebert, D.W., McBride, O.W., and Gonzalez, F.J : Human P₄₅₀: cDNA and complete protein sequence, repetitive alu sequences in the 3' non-translated region and localization of gene to chromosome 15. J Exp Pathol 3: 1-17, 1987.
46. Nebert, D.W., Adesnik, M., Coon, M.J., Estabrook, R.W , Gonzalez, F.J , Guengerich, F P., Gunsalus, I.C., Johnson, E.F , Kemper, B., Levin, W., Phillips, I.R., Sato, R., and Waterman, M.R.: The P-450 gene superfamily. Recommended Nomenclature DNA 6. 1-11, 1987.
47. Nebert, D.W., and Gonzalez, F.J.: P-450 genes and evolutionary genetics. Hosp Pract., March 25, 1987, pp. 63-74.
48. Hong, J., Pan, J., Gonzalez, F.J., Gelboin, H.V., and Yang, C.S.: The induction of a specific form of cytochrome P-450 by fasting. Biochem Biophys Res Commun 142: 1077-1083, 1987.
49. Gonzalez, F.J., Jaiswal, A.K., and Nebert, D.W.: P-450 genes: evolution regulation, and relationship to human cancer. Cold Spring Harbor Symposia on Quantitative Biology, Vol. 51. Molecular Biology of Homo Sapiens, Cold Spring Harbor Laboratory, New York, 1987, pp. 879-890.
50. Nebert, D.W., and Gonzalez, F.J.: P450 genes, structure evolution and regulation. Ann Rev Biochem 56: 945-993, 1987.

51. Jaiswal, A K , Gonzalez, F J., and Nebert, D W . Comparison of human and mouse P₄₅₀ upstream regulatory sequences in liver- and non-liver-derived cell lines. Mol Endocrinol 1: 312-320, 1987
52. Song, B J., Matsunaga, T , Hardwick, J.P., Veech, R.L., Yang, C.S , Gelboin, H.V , and Gonzalez, F.J.. Stabilization of P450_j mRNA in the diabetic rat Mol Endocrinol 1: 542-547, 1987.
53. Nebert, D.W., Jaiswal, A.K., Meyer, U A., and Gonzalez, F J P-450 genes structure, evolution, regulation and relationship to cancer Biochem J. Transactions Royal Soc 15: 586-589, 1987.
54. McBride, O.W., Umeno, M., Gelboin, H.V., and Gonzalez, F J: A Taq I polymorphism in the human P450_{IIIE1} gene on chromosome 10. Nucleic Acids Res 15: 1007, 1987.
55. Kimura, S., Pastewka, J., Gelboin, H V , and Gonzalez, F.J . cDNA and amino acid sequences of two members of the human P450_{IIIC} gene subfamily Nucleic Acids Res 15: 10053-10054, 1987
56. Gonzalez, F.J., Schmid, B , Umeno, M., McBride, O W., Hardwick, J.P., Meyer, U.A., Gelboin, H.V., and Idle, J.R.. Sequence, chromosome localization and direct evidence through cDNA expression that P-450_{PCN1} is nifedipine oxidase. DNA 7: 79-86, 1988.
57. Gonzalez, F.J , Skoda, R., Hardwick, J.P , Song, B.J., Umeno, M., McBride, O.W., Kozak, C., Matsunaga, E., Matsunaga, T., Kimura, S., Parks, S S , Yang, C S., Nebert, D.W., Gelboin, H.V., and Meyer, U.A.: Human and rat debrisoquine 4-hydroxylase and ethanol-inducible P450 gene families: structure and polymorphisms. In: J. Miners, D.J. Birkett, R. Drew, and M. McManus (Eds), Microsomes and Drug Oxidations, Taylor and Francis Ltd., London, England, 1987, pp. 209-215.
58. Meyer, U.A., Catin, T., Demierre, A., Fonne, R., Kronbach, T., Meier, U T., Skoda, R., Vilbois, F., Zanger, U , and Gonzalez, F.J.: Molecular mechanisms of the debrisoquine and mephenytoin-polymorphisms: studies at the protein and DNA level and with circulating autoantibodies against P450_{buf1} (db1) and P450_{meph}. In: J Miners, D.J. Birkett, R. Drew, and M. McManus (Eds.), Microsomes and Drug Oxidation, Taylor and Francis Ltd , London, England, 1987, pp. 201-208.
59. Skoda, R.C., Demierre, A., McBride, O.W., Gonzalez, F.J., and Meyer, U.A.: Human microsomal xenobiotic epoxide hydrolase: cDNA sequence, cDNA directed expression in COS-1 cells and chromosomal localization. J Biol Chem 263: 1549-1554, 1988.
60. Gonzalez, F.J., Skoda, R C., Kimura, S , Umeno, U., Zanger, U.M., Nebert, D.W., Gelboin, H.V., Hardwick, J.P., and Meyer, U.A.: Molecular characterization of the common human deficiency in metabolism of debrisoquine and other drugs. Nature 331: 442-446, 1988.
61. Umeno, M., Song, B.J., Kozak, C., Gelboin, H.V., and Gonzalez, F.J.: The rat P450_{IIIE1} gene: complete intron and exon sequence, chromosome mapping and correlation of developmental expression with specific 5' cytosine demethylation. J Biol Chem 263: 4956-4962, 1988.

62. Gonzalez, F.J., Vilbois, F., Hardwick, J.P., McBride, O W., Nebert, D W., Gelboin, H.V., and Meyer, U.A.. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22 Genomics 2: 174-179, 1988.
63. Skoda, R.C., Gonzalez, F.J., Demierre, A., and Meyer, U.A.: Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A 85: 6240-5243, 1988.
64. Umeno, M., Morris, S., Matsunaga, E., Gelboin, H.V., and Gonzalez, F.J.: Sequence of the 5' end of the developmentally regulated rat P450 PB1 (P450IIC6) gene. Nucleic Acids Res 16: 6249, 1988
65. Gonzalez, F.J.: Variability in response to drug administration can be due to a genetically inherited enzyme deficiency Wellcome Trends Hospital Pharmacy 10: 2-5, 1988.
66. Dong, Z., Hong, J., Ma, Q., Li, D., Bullock, J., Gonzalez, F.J., Park, S.S., Gelboin, H.V., and Yang, C.S.: Mechanism of induction of cytochrome P-450_{ac} (P-450j) in chemically induced and spontaneous diabetic rats. Arch Biochem Biophys. 263: 29-35, 1988.
67. Brooks, B.A., McBride, O W., Dolphin, C.T., Farrall, M., Scambler, P.J., Gonzalez, F.J., and Idle, J.R.: The gene CYP3 encoding P450PCN1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1. Am J Hum Genet. 43 280-284, 1988.
68. Gonzalez, F.J., Matsunaga, E., Umeno, M., Kimura, S., Skoda, R.C., Hardwick, J.P., Gelboin, H.V., and Meyer, U.A.: Structure and evolution of the polymorphic debrisoquine 4-hydroxylase genes in man and rat. In: R. Kato, R.W. Estabrook and M.N. Cayen (Eds.), Xenobiotic Metabolism and Disposition: Proceedings of the 2nd ISSX International Meeting, Taylor and Francis Ltd., London, England, 1989, pp. 21-27.
69. Gonzalez, F.J., Kimura, S., Matsunaga, E., Umeno, M., Aoyama, T., Skoda, R., Vilbois, F., Hardwick, J.P., Nebert, D W., Gelboin, H.V., and Meyer, U.A.. Structure and evolution of the rat and human debrisoquine 4-hydroxylase (P450IID) gene subfamily. In: I. Shuster (Ed.), Proceedings of the 6th International Conference on Biochemistry and Biophysics of Cytochrome P-450, Taylor and Francis Ltd., London, England, 1989, pp.564-567.
70. Song, B.J., Veech, R.L., Park, S.S., Gelboin, H.V., and Gonzalez, F.J.: Structure and regulation of the ethanol-inducible cytochrome P-450j. Advances in Alcoholism and Substance Abuse, Vol. 7, Nos. 3/4, Academic Press Inc. New York, 1988, pp. 205-207.
71. Gelboin, H.V., Gonzalez, F.J., Park, S.S., Sagara, J., and Battula, N.: Cytochrome P-450 function analyses with monoclonal antibodies and cDNA expression vectors. In: F. Feo (Ed.), Proceedings International Meeting on Chemical Carcinogenesis, Plenum Press, Alghero, Italy, 1988, pp. 3-15.

72. Meyer, U A., Skoda, R., Zanger, U , Vilbois, F , and Gonzalez, F J Genetic polymorphisms of drug metabolizing enzymes. In R.W. Estabrook, E. Lindenlaub, F. Oesch and A.L. deWeck (Eds.) Toxicological and Immunological Aspects of Drug Metabolism and Environmental Chemicals, F.K. Shattauer Verlag, Stuttgart-New York, 1988, pp. 229-239.
73. Matsunaga, T., Nagata, K., Holsztyńska, E.J., Lapenson, D P., Smith, A., Kato, R., Gelboin, H V., Waxman, D J., and Gonzalez, F J.: Gene conversion and differential regulation in the rat P450IIA gene subfamily: purification, catalytic activity, cDNA and deduced amino acid sequence and regulation of an adult male-specific hepatic testosterone 15 α -hydroxylase. J Biol Chem 263: 17995-18002, 1988.
74. Umeno, M., McBride, O.W., Yang, C.S., Gelboin, H.V., and Gonzalez, F.J. Human ethanol-inducible P450III β 1' complete gene sequence, promoter characterization, chromosome mapping, regulation, and cDNA directed expression. Biochemistry 27: 9006-9013, 1988.
75. Nebert, D.W., and Gonzalez, F.J.: The P450 gene superfamily In K. Ruckpaul and H. Rein (Eds.) Frontiers in Biotransformation, Vol. 2, Principles, mechanisms and biological consequences of induction. Akademie-Verlag, Berlin, 1990, pp. 35-61.
76. Gonzalez, F J.. The molecular biology of cytochrome P450s. Pharmacol Rev 40: 243-288, 1988.
77. Long, R.M., Satoh, H , Martin, B.M., Kimura, S., Gonzalez, F.J., and Pohl, L.R.. Rat liver carboxylesterase: cDNA cloning, sequencing, and evidence for a multigene family. Biochem Biophys Res Commun 156: 866-873, 1988.
78. Gonzalez, F.J., Matsunaga, T., and Nagata, K.: Structure and regulation of P450s in the rat P450IIA gene subfamily. Drug Metabolism Reviews 20: 827-837, 1989
79. Nebert, D.W. and Gonzalez, F.J : The human P450 gene superfamily and its relationship to malignancy and toxicity. Syllabus for the American Association for The Study of Liver Diseases (AASLD). Chicago: AASLD, 1988, pp 171-178.
80. Song, B J., Veech, R.L., Park, S.S., Gelboin, H.V. and Gonzalez, F.J.: Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem. 264: 3568-3572, 1989.
81. Kimura, S., Kozak, C.A., and Gonzalez, F.J.: Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping, and induction by 3-methylcholanthrene. Biochemistry 28: 3798-3803, 1989.
82. Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F.J. and Meyer, U.A.: Oxidation of midazolam and triazolam by human liver cytochrome P450III λ 4. Molec. Pharmacol. 36: 89-96, 1989.
83. Aoyama, T., Gonzalez, F.J., and Gelboin, H.V.: Mutagen activation by cDNA-expressed P₁450, P₃450 and P450 α . Mol. Carcinog. 1: 253-259, 1989.
84. Aoyama, T., Korzekwa, K , Nagata, K., Gillette, J., Gelboin, H.V , and Gonzalez, F.J.: Rat testosterone 7 α -hydroxylase: cDNA-directed expression using

the modified T7 RNA polymerase vaccinia virus system and evidence for 6 α -hydroxylation and D6-testosterone formation Eur J Biochem. 181: 331-336, 1989.

85. Nhamuro, P T , Gonzalez, F J., McBride, O.W , Gelboin, H.V and Kimura, S.: Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression and chromosome mapping Biochemistry 28: 8060-8068,-1989.
86. Kimura, S., Hanioka, N., Matsunaga, E., and Gonzalez, F J. The rat clofibrate-inducible CYP4A gene subfamily I. Complete intron and exon sequence of the IVA1 (CYP4A1) and IVA2 (CYP4A2) genes, unique exon organization and identification of a conserved 19 base pair upstream element. DNA 8: 503-516, 1989.
87. Kimura, S., Hardwick, J.P., Kozak, C.A., and Gonzalez, F.J.: The rat clofibrate-inducible CYP4A subfamily II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissue-specific regulation of the CYP4A genes. DNA 8: 517-526, 1989.
88. Aoyama, T., Yamano, S., Waxman, D J., Meyer, U.A., Fisher, V., Lapenson, D.P., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H V. and Gonzalez, F.J.: Cytochrome P450 hPCN3, a novel P450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine J Biol Chem. 264: 10388-10395, 1989
89. Yamano, S., Nhamuro, P.T., Aoyama, T., Meyer, U.A., Inaba, T., Kalow, W., Gelboin, H.V., McBride, O W., and Gonzalez, F.J.: cDNA cloning and sequence, and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of IIB mRNAs in human liver. Biochemistry 28: 7340-7348, 1989.
90. Peterson, D.D., Gonzalez, F.J., Rapic, V., Kozak, C A., Lee, J-Y., Jones, J.E., and Nebert, D.W.: Marked increase in hepatic NAD(P)H: oxidoreductase gene transcription and mRNA levels correlated with a mouse chromosome 7 deletion. Proc. Natl Acad Sci U S A., 86: 6699-6703, 1989.
91. Yamano, S., Aoyama, T., McBride, O.W., Hardwick, J.P., Gelboin, H.V., and Gonzalez, F.J.: Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression, and localization of the CYPOR genes to chromosome 7. Mol. Pharmacol. 36: 83-88, 1989.
92. Matsunaga, E., Zanger, U.M., Hardwick, J.P., Gelboin, H.V., Meyer, U.A. and Gonzalez, F.J.: The P450 IID gene subfamily: analysis of the molecular basis of the debriosoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28. 7349-7355, 1989.
93. Yamano, S., Nagata, K., Yamazoe, Y., Kato, R., Gelboin, H.V. and Gonzalez, F.J.: cDNA and deduced amino acid sequences of human IIA3 (CYP2A3). Nucl. Acids Res. 17: 4888, 1989.

94. Asseffa, A., Smith, S., Nagata, K., Gillette, J., Gelboin, H.V. and Gonzalez, F.J. Novel heme-dependent expression of mammalian P450 using baculovirus. Arch Biochem Biophys 274: 481-490, 1989.
95. Bargetzi, M.J., Aoyama, T., Gonzalez, F.J. and Meyer, U.A. Lidocaine metabolism in human liver by cytochrome P450IIIA4 (PCN1). Clin Pharmacol Ther. 46: 521-527, 1989.
96. Aoyama, T., Gonzalez, F.J. and Gelboin, H.V. Human cDNA-expressed cytochrome P450 IA2: Mutagen activation and substrate specificity. Mol Carcinog 2: 40-46, 1989.
97. Kimura, S., Umeno, M., Skoda, R.C., Meyer, U.A. and Gonzalez, F.J.: The human debrisoquine 4-hydroxylase (*CYP2D*) locus: Sequence and identification of the polymorphic *CYP2D6* gene, a related gene and a pseudogene. Amer J Human Genet. 45: 889-904, 1989.
98. Aoyama, T., Korzekwa, K., Nagata, K., Adesnik, M., Reiss, A., Lapenson, D.P., Gillette, J., Gelboin, H.V., Waxman, D.J. and Gonzalez, F.J. Sequence requirements for cytochrome P450 IIB1 catalytic activity: Variation of the stereoselectivity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine. J Biol Chem 264: 21327-21333, 1989.
99. Gonzalez, F.J.: Molecular genetics of the P-450 superfamily. Pharmac Ther 45: 1-38, 1990.
100. Aoyama, T., Korzekwa, K., Matsunaga, T., Nagata, K., Gillette, J., Gelboin, H.V. and Gonzalez, F.J.: cDNA-directed expression of rat P450s IIA1 and IIA2: catalytic activities toward steroids and xenobiotics and comparison with the enzymes purified from liver. Drug Metab Dispos. 18: 378-382, 1990.
101. Matsunaga, E., Umeno, M. and Gonzalez, F.J.: The rat *CYP2D* locus: Complete sequences of four tandemly arranged genes and evidence that gene conversions maintained sequence conservation at the heme-binding region of the cytochrome P450 active site. J Molec Evol 30: 155-169, 1990.
102. Gonzalez, F.J., and Nebert, D.W.: Evolution of the P450 gene superfamily: animal-plant "warfare", molecular drive and human genetic differences in drug oxidation. Trends in Genetics 6:182-187, 1990.
103. Relling, M.V., Aoyama, T., Gonzalez, F.J. and Meyer, U.A.: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the *CYP2C* subfamily. J Pharm Exp Ther. 252: 442-447, 1990.
104. Aoyama, T., Gelboin, H.V. and Gonzalez, F.J.: Mutagenic activation of 2-amino-3-methylimidazo [4,5-f] quinoline (IQ) by cDNA-expressed human liver P450. Cancer Res. 50: 2060-2063, 1990.
105. Niznik, H.B., Tyndale, R.F., Sallee, R., Gonzalez, F.J., Hardwick, J.P., Inaba, T., and Kalow, W.: The dopamine transporter and cytochrome P450 db1 (debrisoquine 4-hydroxylase) in brain: Resolution and identification of two distinct [³H]GBR-12935 binding proteins. Arch Biochem Biophys. 276: 424-432, 1990.

106. Gonzalez, F.J. Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility Birth Defects 26 17-42, 1990
107. Yamano, S., Tatsuno, J. and Gonzalez, F.J.. The *CYP2A3* gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29 1322-1329, 1990.
108. Matsunaga, T, Nomoto, M., Kozak, C.A. and Gonzalez, F.J.. Structure and *in vitro* transcription of the rat *CYP2A1* and *CYP2A2* genes and regional localization of the *CYP2A* gene subfamily on mouse chromosome 7 Biochemistry 29. 1329-1341, 1990.
109. Gonzalez, F.J., Aoyama, T. and Gelboin, H.V.: Activation of promutagens by human cDNA-expressed cytochrome P450s. In M Mendelsohn (Ed.) Mutation and the environment, part B, Proceedings of the Fifth International Conference on Environmental Mutagens, Wiley-Liss, Inc., New York, pp. 77-86, 1990.
110. Nagata, K., Gonzalez, F.J., Yamazoe, Y., and Kato, R.: Purification and characterization of a novel catalytically active testosterone 6 β -hydroxylase P450 from rat liver microsomes. comparisons with three structurally and functionally related forms. J Biochem. 107: 718-725, 1990.
111. Nebert, D.W., and Gonzalez, F.J.: Cytochrome P450 nomenclature Drug Metab Newsletter 19: 2-3, 1989.
112. Gonzalez, F.J.: Human cytochrome P450: possible roles of drug metabolizing enzymes and polymorphic drug oxidation in addiction. In T.N H. Lee (Ed.) Molecular approaches to drug abuse research, Vol 1. NIDA Research Monograph 111, pp 202-213, 1991.
113. Gonzalez, F.J.: Cytochrome P450. In: Encyclopedia of human biology, Vol. 2, Academic Press Inc., New York pp. 737-749, 1991. *
114. Crespi, C.L., Steimel, D.T., Aoyama, T., Gelboin, H.V. and Gonzalez, F.J : Stable expression of human cytochrome P450IA2 cDNA in a human lymphoblastoid cell line: role of the enzyme in the metabolic activation of aflatoxin B₁ Mol Carcinog. 3. 1-5, 1990.
115. Robinson, R.C., Nagata, K., Gelboin, H.V., Rifkind, J., Gonzalez, F.J., and Friedman, F.K.: Developmental regulation of hepatic testosterone hydroxylases: simultaneous activation and repression of constitutively expressed cytochromes P-450 in senescent rats. Arch. Biochem. Biophys. 277: 42-46, 1990.
116. Miles, J.S., McLaren, A.W., Gonzalez, F.J and Wolf, C.R.: Alternative splicing in the human cytochrome P450IIIB6 gene: use of a cryptic exon within 3 and splice acceptor site within exon 4. Nucl Acids Res 18. 189, 1990.
117. Aoyama, T., Korzekwa, K., Gillette, J., Gelboin, H.V., and Gonzalez, F.J.: Estradiol metabolism by human cytochrome P450s. Endocrinology 126.3101-3106, 1990.
118. Nhamburo, P.T, Kimura, S., McBride O W, Kozak, C.A., Gelboin, H.V. and Gonzalez, F.J.: The human *CYP2F* subfamily: Identification of a cDNA coding for

- a new cytochrome P450 expressed in lung, cDNA-directed expression and chromosome mapping Biochemistry 29 5491-5499, 1990.
- 119 Tyndale, R.F , Gonzalez, F J , Hardwick, J P , Inaba, T , and Kalow, W
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunocytochemistry. Pharmacol Toxicol 67:14-18, 1990
 120. Matsunaga, E , Zeugin, T., Zanger, U.M , Aoyama, T., Meyer, U.A and Gonzalez, F.J.: Sequence requirements for cytochrome P450IID1 catalytic activity: A single amino acid change (Ile₃₈₀→Phe) specifically decreases V_{max} of the enzyme for bufuralol but not debrisoquine hydroxylation. J Biol Chem 265:17197-17201, 1990
 121. Aoyama, T., Hardwick, J.P., Imaoka, S., Funai, Y., Gelboin, H V , and Gonzalez, F.J : Clofibrate-inducible rat hepatic P450IVA3 catalyzes the ω- and (ω-1)-hydroxylation of fatty acids and the ω-hydroxylation of prostaglandins E₁ and F_{2a} J Lipid Res 31:1477-1482, 1990
 122. Hanioka, N., Korzekwa, K , and Gonzalez, F.J. Sequence requirements for cytochrome P450IIA1 and P450IIA2 catalytic activity: evidence for both specific and non-specific substrate binding interactions through use of chimeric cDNAs and cDNA expression. Prot Engng. 3:571-575, 1990.
 123. Sugimura, H , Caporaso, N.E., Shaw, G.L., Modali, R.V., Gonzalez, F.J., Hoover, R.N., Resau, J.H., Trump, B.F , Weston, A., and Harris, C C : Human debrisoquine 4-hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis 11:1527-1530, 1990
 124. Aoyama, T., Yamano, S , Guzelian, P.S., Gelboin, H.V and Gonzalez, F.J : Five of 12 forms of human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci, U S A., 87:4790-4793, 1990.
 125. Aoyama, T., Nagata, K. Yamazoe, Y , Kato, R , Matsunaga, E., Gelboin, H V , and Gonzalez, F.J : Cytochrome b₅ potentiation of the P450 mixed function monooxygenase system demonstrated by a novel vaccinia virus-mediated *in situ* reconstitution system. Proc Natl Acad Sci, U S A., 87:5424-5429, 1990.
 126. Howard, P C., Aoyama, T., Bauer, S.L., Gelboin, H.V., and Gonzalez, F.J.. Metabolism of 1-nitropyrene by human cytochromes P450 Carcinogenesis 11:1539-1542, 1990.
 127. Ueno, T. and Gonzalez, F.J.: Complete sequence of the rat *CYP2A3* gene specifically transcribed in rat lung. Nucl Acids Res. 15:4623-4624, 1990.
 128. Gonzalez, F.J., Aoyama, T., and Gelboin, H.V.: Expression of mammalian cytochrome P450 using vaccinia virus. Meth Enzymol 206:85-92, 1991.
 129. Matsunaga, E., and Gonzalez, F.J.: Developmental regulation of the rat P450IID genes: Specific cytosine demethylation within the first exons of the rat *CYP2D3* and *CYP2D5* genes are associated with activation of hepatic gene expression during development. DNA Cell Biol 9: 443-452, 1990.
 130. Ueno, T., and Gonzalez, F.J : Transcriptional control of the rat hepatic *CYP2E1* gene. Mol. Cell Biol. 10:4495-4505, 1990.

131. Hanioka, N , Kimura, S , Meyer, U A. and Gonzalez, F J. The human CYP2D locus associated with a common genetic defect in drug oxidation. A G₁₉₃₄ → A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Amer J Hum Genet 47 994-1001, 1990.
132. Gonzalez, F J , Ueno, T , Umeno, M., Song, B J , Veech, R.L. and Gelboin, H V.. Microsomal ethanol oxidizing system. transcriptional and posttranscriptional regulation of cytochrome P450, CYP2E1 In: H Kalant, J.M. Khanna and Y. Israel (Eds), (In press). Advances in Biomedical Alcohol Research, Pergamon Press, New York pp. 97-101, 1991.
133. Gonzalez, F.J., Crespi, C.L. and Gelboin, H.V.: cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat Res. 247:113-127, 1991.
134. Gonzalez, F.J., Kimura, S., Tamura, S and Gelboin, H.V.: Expression of mammalian cytochrome P450 using baculovirus Meth Enzymol 206.93-99, 1991.
135. Gonzalez, F.J., Liu, S-Y., Kozak, C.A. and Nebert, D.W.: Decreased Hnf-1 gene expression in mice homozygous for a 1.2 centiMorgan deletion on chromosome 7. DNA Cell Biol 9:771-776, 1990.
136. Kikkawa, F., Gonzalez, F.J and Kimura, S.: Characterization of a thyroid-specific enhancer located 5.5 kbp upstream of the human thyroid peroxidase gene. Mol Cell Biol 10:6216-6224, 1990
137. Hardwick, J.P., Russel, J.J , Kimura, S., Gonzalez, F.J., Reddy, J., Peraino, C. and Huberman, E . Localization and expression of the eicosanoid metabolizing P450IVA gene family in rat tissues and hepatic tumors. In: K.V Honn, L.J. Marnett, S Nigam and T. Walden, Jr , (Eds.) Eicosanoids and other bioactive lipids in cancer and radiation injury Kluwer Academic Publishers, United Kingdom pp. 37-41, 1991.
138. Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook, R.W., Feyereisen, R., Fujii-Kuriyama, Y , Gonzalez, F J., Guengerich, F P., Gunsalus, I.C., Johnson, E.F., Loper, J.C , Sato, R., Waterman, M R. and Waxman, D J : The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10.1-14, 1991.
139. Gonzalez, F.J.: Transcriptional and post-transcriptional regulation of rat hepatic CYP2E1. In: K.W. Bock, W. Gerok, S. Matern, R. Schmid (Eds), Proceedings, Falk Symposium No. 57: Hepatic Metabolism and Disposition of Endo- and Xenobiotics. Kluwer Academic Publishers, United Kingdom, pp. 77-89, 1991.
140. Gonzalez, F.J. and Gelboin, H.V.. Human cytochromes P450: evolution, catalytic activities and interindividual variations in expression. In: B.L. Gledhill, F. Mauro (Eds), Progress in Clinical and Biological Research, Vol. 372, New Horizons in Biological Dosimetry Wiley-Liss Inc. New York, pp. 11-20, 1991.
141. Crespi, C.L., Penman, B.W., Steimel, D.T., Gelboin, H.V. and Gonzalez, F.J.: The development of a human cell line stably expressing human CYP3A4: role in the

metabolic activation of aflatoxin B₁ and comparison to CYP1A2 and CYP2A3
Carcinogenesis. 12 355-359, 1991.

142. Gelboin, H.V., Park, S.S., Aoyama, T., Crespi, C.L., and Gonzalez, F.J. Mapping of cytochrome P450 distribution and function with monoclonal antibodies and cDNA expression. In: L. Ernster, H. Esumi, Y. Fujii, H.V. Gelboin, R. Kato, and T. Sugimura (Eds.), Proceedings of the 21st International Symposium of the Princess Takamatsu Cancer Research Fund, Xenobiotics and Cancer: Implications for Chemical Carcinogenesis and Cancer Therapy Japan Scientific Societies Press, Tokyo, pp. 157-164, 1991.
143. Gonzalez, F.J. and Gelboin, H.V.: Transcriptional and posttranscriptional regulation of CYP2E1, an N-nitrosodimethylamine demethylase. In: L. Ernster, H. Esumi, Y. Fujii, H.V. Gelboin, R. Kato, and T. Sugimura (Eds.), Proceedings of the 21st International Symposium of The Princess Takamatsu Cancer Research Fund, Xenobiotics and Cancer: Implications for Chemical Carcinogenesis and Cancer Chemotherapy. Japan Scientific Societies Press, Tokyo, pp. 3-16, 1991
144. Crespi, C.L., Penman, B.W., Gelboin, H.V. and Gonzalez, F.J.: A tobacco smoke-derived nitrosamine, 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butone (NNK), is activated by the polymorphic human cytochrome P4502D6 (CYP2D6). Carcinogenesis 12:1197-1201, 1991.
145. Bale, A.E., Mitchell, A.L., Gonzalez, F.J. and McBride, O.W.: Localization of the CYP2F1 gene by multi-point linkage analysis and pulsed field gel electrophoresis. Genomics 10:284-286, 1991.
146. Tyndale, R., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F.J. and Niznik, H.B. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type) potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6 Molec Pharmacol 40:63-68, 1991.
147. Waxman, D.J., Lapenson, D.P., Aoyama, T., Gelboin, H.V., Gonzalez, F.J. and Korzekwa, K.: Steroid hormone hydroxylase specificities of twelve cDNA-expressed human cytochromes P-450s. Arch Biochem Biophys. 290:160-166, 1991.
148. Gonzalez, F.J. and Meyer, U.A.: Molecular genetics of the debrisoquine/sparteine polymorphism. Clin Pharm Ther 50:233-238, 1991.
149. Czerwinski, M., McLemore, T.L., Philpot, R.M., Nhamburo, P.T., Korzekwa, K., Gelboin, H.V. and Gonzalez, F.J.: Metabolic activation of 4-ipomeanol by cDNA-expressed human cytochromes P450: evidence for species-specific metabolism. Cancer Res. 51:4639-4642, 1991.
150. Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H.V., Meyer, U.A., Gonzalez, F.J.: Identification of a new CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26-32, 1991.
151. Furuya, H., Meyer, U.A., Gelboin, H.V. and Gonzalez, F.J.: Polymerase chain reaction-directed identification, cloning and quantification of human CYP2C18 mRNA. Mol Pharmacol 40:375-382, 1991.

152. Gonzalez, F J and Gelboin, H.V.. Complementary DNA-directed expression of human cytochromes P450 In E.H. Jeffery (ed), Human metabolism. from molecular biology to man, CRC Press, Boca Raton, pp. 13-21, 1993
153. Crespi, C.L., Gonzalez, F J., Steimel, D.T., Turner, T.R., Gelboin, H.V , Penman, B.W., and Langenbach, R.: A metabolically competent human cell line expressing 5 cDNAs encoding procarcinogen-activating enzymes. application to mutagenicity testing Chem Res Toxicol 4:566-572, 1991.
154. Gonzalez, F.J. and Gelboin, H V.: Human cytochrome P450 evolution and cDNA-directed expression. In I.K. O'Neill and H. Bartsch (eds.), Proceedings of the IARC symposium on Biomonitoring and susceptibility markers in human cancer: applications in molecular epidemiology and risk assessment. Envir Health Perspec. 98:81-85, 1992.
155. Gonzalez, F.J.: P450 in humans. In: J.B. Schenkman and H Greim (Eds.) Cytochrome P-450. Handbook of Experimental Pharmacology Springer-Verlag, Heidelberg, pp. 239-257, 1993.
156. Gonzalez, F.J.: P450 evolution and nomenclature. In: J.B. Schenkman and H. Greim (Eds.) Cytochrome P-450. Handbook of Experimental Pharmacology. Springer-Verlag, Heidelberg, pp. 211-219, 1993.
157. Kondo, I., Yonaha, M., Okano, K., Gonzalez, F.J. and Kanazawa, I.: Identifcation of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population. Pharmacogenetics 1. 161-164, 1991.
158. Mizuno, K., Gonzalez, F.J. and Kimura, S. Thyroid-specific enhancer-binding protein (T/EBP). cDNA cloning, functional characterization and structural identity with thyroid transcription factor TTF-1. Mol Cell Biol. 11: 4927-4933, 1991.
159. Tamura, S., Korzekwa, K.R., Kimura, S , Gelboin, H.V. and Gonzalez, F.J.: Baculovirus-mediated expression and funcuonal characterization of human NADPH-P450 oxidoreductase. Arch Biochem Biophys. 293. 219-223, 1992.
160. Gonzalez, F.J.: Human cytochromes P450: analysis through use of complementary DNA-directed expression. In: A. Archakov and G.I Bachmanova (Eds.), Biochemistry and Biophysics, Cytochrome P-450 Proceedings 7th International Conference, INCO-TNG, Joint Stock Co., Moscow, pp 333-338, 1993.
161. Rettie, A.E., Korzekwa, K.K., Kunze, K.L., Lawrence, R.F , Eddyll, A.C., Aoyama, T., Gelboin, H.V., Gonzalez, F.J. and Trager, W.F.. Hydroxylation of warfarin by human liver cytochrome P-450: a role for proteins encoded by CYP2C9 in the etiology of anticoagulation drug interactions. Chem Res Toxicol. 5, 54-59, 1992
162. Krishna, M.C., DeGraf, W., Tamura, S., Gonzalez, F.J., Samuni, A., Russo, A. and Mitchell, J.B.: Evaluation of the mechanisms of hypoxic and aerobic cytotoxicity of mitomycin C in Chinese hamster V79 cells using a stable nitroxide cyclic antioxidant. Cancer Res 51:6622-6628. 1991.
163. Christou, M., Mitchell, M., Aoyama, T., Gelboin, H.V., Gonzalez, F.J., and Jefcoate, C.R.: Selective suppression of catalytic activity of cDNA-expressed cytochrome P4502B1 toward polycyclic hydrocarbons in the microsomal

membrane modification of this effect by specific amino acid substitutions. Biochemistry 31:2835-2841, 1992.

164. deWaziers, I, Bouguet, L, Beaune, P H , Gonzalez, F.J , Ketterer, B , and Barouki, R.: Effects of ethanol, dexamethasone and RU486 on expression of cytochrome P450 2B, 2E, 3A and glutathione transferase in a rat hepatoma cell line (Fao). Pharmacogenetics 2 12-18, 1992.
165. Gonzalez, F J., Crespi, C L., Czerwinski, M. and Gelboin, H.V : Analysis of human cytochrome P450 catalytic activities and expression. Tohoku J Exp Med 168:67-72, 1992.
166. Hanioka, N., Gonzalez, F J., Lindberg, N.A., Liu, G., Gelboin, H.V. and Korzekwa, K.R.: Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: Influence of the distal helix on the kinetics of testosterone hydroxylation. Biochemistry 31: 3364-3370, 1992.
167. Thornton-Manning, J R , Ruangyuttikarn, W., Gonzalez, F J. and Yost, G R.. Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s Biochem Biophys Res Commun 181 100-107, 1991.
168. Gonzalez, F.J.: Molecular biology of human xenobiotic-metabolizing cytochromes P450: role of vaccinia virus cDNA expression in evaluating catalytic function. Toxicology 82:77-88, 1993.
169. Gu, L., Gonzalez, F.J., Kalow, W. and Tang, B K.: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1 Pharmacogenetics 2:73-77, 1992
170. Hanioka, N., Gonzalez, F J., Lindberg, N.A , Liu, G and Korzekwa, K.R.. Chimeric cDNA expression and site directed mutagenesis studies of cytochrome P450s CYP2A1 and CYP2A2. J Steroid Biochem Mol Biol 43.1037-1043, 1992.
171. Cholerton, S , Idle, M.E., Vas, A., Gonzalez, F.J., and Idle, J.R. Comparison of a novel thin-layer chromatography-fluorescence detection method with spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatog. 575:325-330, 1992.
172. Gonzalez, F.J: Control of constitutively-expressed developmentally-activated rat hepatic cytochrome P450 genes. Keio J Med. 41:68-75, 1992.
173. Smith, T.J., Guo, Z., Gonzalez, F J., Guengerich, F.P., Stoner, G D. and Yang, C.S.: Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung and liver microsomes and in human hepatoma cells containing cDNA-expressed cytochromes P-450 Cancer Res. 52:1757-1763, 1992.
174. Wolfe, C., Hoinrich-Hirsch, B , Schulz-Schalge, T., Seidel, A., Frank, H., Ramp, U., Wachter, F., Wiebel, F.J., Gonzalez, F.J. and Doehmer, J.: Genetically engineered V79 Chinese hamster cells for stable expression of human cytochrome P450IA2 cDNA. Eur J Pharmacol. 228:95-102, 1992
175. Gonzalez, F J.: Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 13:346-352, 1992.

176. Yano, M., Falvey, E and Gonzalez, F J . Role of the liver-enriched transcription factor DBP in expression of the cytochrome P450 CYP2C6 gene Mol Cell Biol 12:2847-2854, 1992.
177. Flammang, A.M., Gelboin, H.V , Aoyama, T , Gonzalez, F J and McCoy, G D : Nicotine metabolism by human cDNA-expressed cytochrome P-450 Biochem Arch 8. 1-8, 1992.
178. Gonzalez, F.J . In vitro systems for prediction of rates of drug clearance and drug-drug interactions. Anesthesiology. 77:413-415, 1992.
179. Smith, S.J., Korzekwa, K , Aoyama, T., Gonzalez, F.J., Darbyshire, J.F., Sugiyama, K., and Gillette, J.: 12 α -Hydroxytestosterone: a hitherto unidentified testosterone metabolite produced by cytochrome P450 2A2. Drug Metab Disp 20:566-571, 1992.
180. Nebert, D.W , and Gonzalez, F.J.: "Oxidative Stress" response and abnormal gluconeogenesis in a mouse having a 1.2-cM deletion on chromosome 7 In DNA and Free Radicals, Ellis Horwood Ltd., UK.
181. Park, S.S., Walker, W., Aoyama, T., Lapenson, D., Waxman, D.J., Gonzalez, F.J. and Gelboin, H.V. Monoclonal antibodies to rat cytochrome b₅ which recognizes rabbit microsomal and human cDNA-expressed cytochrome b₅. Biochem Pharmacol. 43:2201-2208, 1992.
182. Patten, C.J , Ishizaki, H., Aoyama, T., Lee, M., Ning, S.M., Huang, W., Gonzalez, F.J., and Yang, C S : Catalytic properties of the human cytochrome P450 2E1 produced by cDNA expression in mammalian cells Arch Biochem Biophys 299:163-171, 1992.
183. Kapitulnik, J, and Gonzalez, F. J.: The role of cytochrome P-450 in the elimination of bilirubin in congenital Jaundice (Crigler-Nijjar Syndrome Type 1). J Basic Clin Physiol Pharmacol 3:90-91, 1992.
184. Gonzalez, F.J. and Gelboin, H.V.: Cytochrome P450s and molecular epidemiology. In: T. Vo-Dinh and K. Cammann (Eds.), Proceedings Europto Series, International Conference on Monitoring of Toxic Chemicals and Biomarkers, Vol. 1716, SPIE, Bellingham WA, pp 224-235, 1993.
185. Penman, B.W , Reece, J., Smith, T., Yang, C.S., Gelboin, H V., Gonzalez, F J. and Crespi, C.L.: Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics. 3:28-39, 1993.
186. Gonzalez, F.J., Yano, M., Liu, S.Y: Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics. 3:51-57, 1993.
187. Crespi, C.L., Langenbach, R., Gonzalez, F.J., Gelboin, H.V., and Penman, B.W.: Development of human cell lines engineered to metabolically activate structurally diverse environmental mutagens. In: T. Vo-Dinh and K. Cammann (Eds.), Proceedings Europto Series, International Conference on Monitoring of Toxic Chemicals and Biomarkers, Vol. 1716, SPIE Bellingham WA, pp 268-274, 1993.

- 188 Tassaneeyakul, W., Mohamed, Z., Birkett, D J , McManus, M E , Tukey, R H., Gonzalez, F.J., and Miners, J O . Caffeine as a probe for human cytochromes P450 validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibition techniques. Pharmacogenetics 2:173-183, 1992
189. Nelson, D R., Kamataki, T., Coon, M.J., Estabrook, R.W., Feyereisen, R , Gonzalez, F.J., Gotoh, O , Guengerich, F.P., Gunsalus, I.C., Ikuda, K , Waxman, D J. and Nebert, D W : The P450 superfamily Update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature DNA Cell Biol 12:1-51, 1993.
- 190 Silvers, K K., Chazinski, T., McManus, M E , Bauer, S L., Gonzalez, F J., Gelboin, H.V , Maurel, P., and Howard, P.C.: Cytochrome P450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. Cancer Res 52:6237-6243, 1992.
191. Tiano, H.F , Hosokawa, M., Chulada, P C., Smith, P.B., Wang, R L., Gonzalez, F.J., Crespi, C.L., and Langenbach, R.: Retroviral mediated transfer of human cytochrome P450 2A6 into C3H/10T 1/2 cells confers transformability by 4-(methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) Carcinogenesis. 14. 1421-1427, 1993.
192. Kapitulnik, J and Gonzalez, F J.. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat Molec Pharmacol 43:722-725, 1993.
193. Wedlund, P. J., Kimura, S., Gonzalez, F. J , and Nebert, D.: I462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9-kb (M2) allele and CYP1A1 inducibility in a 15-member 3-generation family of east mediterranean descent Pharmacogenetics 4. 21-26, 1994.
194. Sher, T., Yi, H F , McBride, O.W , and Gonzalez, F.J.: cDNA cloning, chromosome mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604, 1993.
195. Gonzalez, F.J. and Gelboin, H.V.: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews 26:165-183, 1994.
196. Patten, C.J., Thomas, P E., Guy, R.L., Lee, M., Gonzalez, F.J. Guengerich, F.P., and Yang, C.S.. Kinetics and cytochrome P450 enzymes involvement in acetaminophen activation by rat and human liver microsomes. Chem Res Toxicol 6:511-518, 1993.
197. Gonzalez, F J. and Gelboin, H.V.: Role of human cytochromes P450 in risk assessment and susceptibility to environmentally-based disease. J Toxicol Envir Health 40:289-308, 1993.
198. Imaoka, S., Ogawa, H., Kimura, S , and Gonzalez, F. J.: Complete cDNA sequence and cDNA expression of CYP4A11, a fatty acid hydroxylase expressed in human kidney DNA Cell Biol. 12:893-899, 1993.

199. Goldfarb, I., Korzekwa, K., Krausz, K.W., Gonzalez, F.J., and Gelboin, H.V. Cross reactivity of 13 monoclonal antibodies with vaccinia virus expressed rat, mouse and human cytochrome P450s. Biochem Pharmacol 46:787-790, 1993
200. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Kondo, I., Gonzalez, F.J.: Evidence for a new variant CYP2D6 allele (CYP2D6J), associated with lower rates of sparteine metabolism. Pharmacogenetics 3 256-263, 1993.
201. Roberts-Thomson, S.J., McManus, M.E., Tukey, R.H., Gonzalez, F.J. and Holder, G.M.: The catalytic activation of four cDNA-expressed human cytochrome P450s towards benzo(a)pyrene and the isomers of its proximate carcinogen. Biochem Biophys Res Commun 192:1373-1374, 1993
202. Imaoka, S., Wedlund, P., Kimura, S., Gonzalez, F.J., Kim, H-Y.: Evidence that CYP2C23 expressed in rat kidney is an arachidonic acid epoxygenase. J Pharmacol Exp Ther 267:1012-1016, 1993.
203. Gonzalez, F.J. and Idle, J.R.: Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinetics 26: 59-70, 1994.
204. Kroetz, D.L., McBride, O.W. and Gonzalez, F.J.: Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases. cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry 32:11606-11617, 1993.
205. Rettie, A.E., Wienkers, L.C., Gonzalez, F.J., Trager, W.F., and Korzekwa, K.K.: Deficient (S)-warfarin metabolism catalyzed by the R144C variant of CYP2C9. Pharmacogenetics 4, 39-42, 1994.
206. Mimura, M., Baba, T., Yamazaki, H., Ohmori, S., Inui, Y., Gonzalez, F.J., Guengerich, F.P. and Shimada, T.: Characterization of cytochrome P450 2B6 in human liver microsomes Drug Metab Disp 21. 1383-1394, 1993.
207. Tassaneeyakal, W., Veronese, M., Birkett, D.J., Gonzalez, F.J., McManus, M.E., and Miners, J.O.: Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA-expression and microsomal kinetic techniques. Biochem Pharmacol 46: 1975-1981, 1993.
208. Lee, Y.-H., Yano, M., Liu, S.-Y., Matsunaga, E., Johnson, P. F. and Gonzalez, F.J.: A novel cis-acting element controlling the rat CYP2D5 gene requiring cooperativity between C/EBP β , and an Sp1 factor. Mol Cell Biol. 14: 1383-1394, 1994.
209. Birkett, D.J., Rees, D., Anderson, T., Gonzalez, F.J., Miners, J.O. and Veronese, M.E.: Proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Brit J Clin Pharmacol. 37: 413-420, 1994.
210. Czerwinski, M., McLemore, T.L., Gelboin, H.V. and Gonzalez, F.J.: Quantification of CYP2B7, CYP4B1 and CYPOR mRNAs in normal human lung and lung tumors. Cancer Res. 54: 1085-1091, 1994.
211. Yamazaki, H., Mimura, M., Oda, Y., Gonzalez, F.J., El-Bayoumi, K., Guengerich, F.P. and Shimada, T.: Activation of trans-1,2-dihydro 1,2-dihydroxy-

- 6-aminochrysene to genotoxic metabolites by cytochromes P450 enzymes in rat and human microsomes. Carcinogenesis 15 465-470, 1994
212. Schmalix, W A., Masser, H., Kiefer, F., Reen, R., Weibel, F.J , Gonzalez, F J , Seidel, A , Glatt, H , Greim, H. and Doehmer, J.: Stable expression of human cytochrome P450 1A1 cDNA in V79 Chinese Hamster cells and metabolic activation of benzo(a)pyrene Eur J Toxicol Pharmacol 248:251-261, 1993
 213. Relling, M.V , Nemec, J , Schuetz, E., Gonzalez, F.J., and Korzekwa, K.K · Epipodophyllotoxin O-demethylation catalyzed by human cytochrome P4503A4 Mol Pharmacol 45:352-358, 1994.
 214. McKinnon, R.A., Burgess, W.M., Gonzalez, F.J., and McManus, M.E.: Metabolic differences in colon mucosal cells. Mutat Res, 290:27-33, 1993.
 215. Nakajima, T., Elovaara, E., Gonzalez, F J., Gelbion, H.V., Vaino, H., and Aoyama, T.: Characterization of human cytochrome P450 isozymes responsible for styrene metabolism. IARC Sci Publ 127: 101-108, 1993.
 216. Nakajima, T., Wang, R -S , Elovaara, E., Gonzalez, F.J., Gelbion, H.V., and Aoyama, T.: CYP2C1 and CYP2B1 are major cytochrome P450 forms involved in styrene oxidation in liver and lung microsomes from untreated rat, respectively. Biochem Pharm 48: 637-642, 1994.
 217. Shou, M., Korzekwa, K.R., Crespi, C.L., Gonzalez, F.J and Gelboin, H.V.: The role of twelve cDNA expressed human and rodent cytochrome P450s in the metabolism of benzo(a)pyrene and benzo(a)pyrene trans-7,8-dihydrodiol. Mol. Carcinog, 10: 159-168, 1994.
 218. Kerr, B M., Thummel, K.E., Warden, C.J , Klein, S M., Kroetz, D.L., Gonzalez, F J and Levy, R.H.: Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol 47· 1969-1979, 1994.
 219. Yanagawa, Y., Sawada, M , Deguchi, T., Gonzalez, F.J., and Kamataki, T.: Stable expression of human CYP1A2 and N-acetyltransferases: Mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-3,8,-dimethylimidazo[4,5-f]quinoxaline (MeIQx). Cancer Res 54 3422-3427, 1994.
 220. Shou, M., Grogan, J., Mancewicz, J.A., Krausz, K.W , Gonzalez, F.J , Gelboin, H.V. and Korzekwa, K.R.: Activation of CYP3A4: Simultaneous occupation of two substrates in a cytochrome P450 active site. Biochemistry 33· 6450-6455, 1994.
 221. Lee, Y.-H., Alberta, J.A., Gonzalez, F.J., and Waxman, D.J.: Multiple, functional DBP-binding sites on the promoter of the cholesterol 7 α -hydroxylase P450 gene CYP7: proposed role in diurnal regulation of liver gene expression. J Biol Chem 269: 14681-14689, 1994.
 222. Crespi, C.L., Langenbach, R., Gelboin, H.V., Gonzalez, F.J., Penman, B.W.: Human cells as an expression system for cytochromes P450. In: Assessment of the use of single cytochrome P450 enzymes in drug research. M. Hildebrand and M. Waterman, Eds., Springer Verlag, Berlin pp. 111-134, 1994.

223. Gonzalez, F.J. Regulation of xenobiotic metabolizing cytochromes P450. In: Assessment of the use of single cytochrome P450 enzymes in drug research. M. Hildebrand and M. Waterman, Eds., Springer Verlag, Berlin pp 21-42, 1994.
224. Gonzalez, F.J.: Human cytochromes P450. In: Principles of Antineoplastic Drug Development and Pharmacology (R.L. Shilsky, G.A. Milano, M.J. Ratan, Eds.) Marcel Dekker Inc., New York, pp 307-327, 1996
225. Matsunaga, T., Watanabe, K., Yamamoto, I., Negishi, M., Gonzalez, F.J., and Yoshimura, H.: cDNA cloning and sequence of CYP2C29 encoding P-450 MUT-2, a microsomal aldehyde oxygenase Biochim Biophys Acta 1184: 299-301, 1994.
226. Chang, T.K., Gonzalez, F.J. and Waxman, D.J. Evaluation of triacetyloleadomycin, naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450 Arch Biochem Biophys 311: 437-442, 1994.
227. Shou, M., Korzekwa, K.R., Krausz, K.W., Crespi, C.L., Gonzalez, F.J., and Gelboin, H.V.: Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA expressed human and rodent cytochromes P450. Cancer Lett 83: 305-313, 1994.
228. Herscher, L.L., Krishna, M.C., Cook, J.A., Coleman, C.N., Biaglow, J.E., Tuttle, S.W., Gonzalez, F.J., and Mitchell, J.B.: Protection against SR 4233 (tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Int. J. Rad. Oncol 30: 879-885, 1994.
229. Gonzalez, F.J.. The CYP2D subfamily. In: Cytochromes P450: Metabolic and Toxicological Aspects, C. Ioannides Ed, CRC Press, Boca Raton FL pp. 183-210, 1996.
230. Penman, B.W., Chen, L., Gelboin, H.V., Gonzalez, F.J., and Crespi, C.L.: Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1: substrate specificity with model substrates and promutagens. Carcinogenesis 15: 1931-1937, 1994.
231. Gonzalez, F.J.: Xenobiotic-metabolizing enzymes in biomarker research. In: Biomarkers and Occupational Health (Mendelson, M.L., Peters, J.P. and Normandy, M.J, Eds.) Joseph Henry Press, Washington D.C., pp 238-256, 1995.
232. Gonzalez, F.J.: CYP2D subfamily. In: Cytochromes P450, Metabolic and Toxicologic Aspects, C. Ioannides, Ed., CRC Press, Boca Raton FL, pp 183-210, 1996.
233. Mace, K., Gonzalez, F.J., McConnell, I.R., Garner, R.C., Avanti, O., Harris, C.C., and Pfeifer, A.: Increased activation of promutagens in a human bronchial epithelial cell line stably expressing the human CYP1A2. Mol. Carcinog. 11: 65-73, 1994.
234. McKinnon, R.A., Burgess, W.M., Gonzalez, F.J., Gasser, R., and McManus, M.E.: Characterization of CYP4B1 expression in rabbit and human gastrointestinal tissues. Pharmacogenetics 4: 260-270, 1994.

235. Buters, J.T.M , Korzekwa, K.R., Kunze, K.L , Omata, Y., Hardwick, J P , and Gonzalez, F G.: cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Disp 22: 688-692, 1994
236. McKinnon, R A., Burgess, W M., Roberts-Thomson, S J , Hall, P , Gonzalez, F J. and McManus, M E.. Characterization of CYP3A expression in human gastrointestinal tissues. Gut 36 259-267, 1995
237. Flammang, A.M , Gelboin, H.V., Aoyama, T., Gonzalez, F J., and McCoy, G D.: N-Nitrosopyrrolidine metabolism by cDNA-expressed human cytochrome P450s. Biochem Arch 9.197-204, 1993.
238. Yokota, H., Fernandez-Salguero, P., Furuya, H., Lin, K., McBride, O W , Podschun, B., Schnackerz, K.D. and Gonzalez, F.J : cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uracilurea J Biol Chem 269: 23192-23196, 1994.
239. Takai, S., Fernandez-Salguero, P., Kimura, S., Gonzalez, F J.: Assignment of the human Dihydropyrimidine dehydrogenase gene to 1p22 by fluorescence in situ hybridization. Genomics 24. 613-614, 1994.
240. Lee, Y.-H., and Gonzalez, F J.. Mechanisms of liver-specific expression of the CYP2D5 gene. In: Cytochrome P450 Biochemistry, Biophysics and Molecular Biology. M C. Lechner, Ed., John Libbey Eurotext, Paris, pp 59-65, 1994.
241. Gonzalez, F J., and Korzekwa, K. R.: Cytochromes P450 expression systems. Annu Rev. Pharmacol Toxicol 35: 369-390, 1995.
242. Shou, M., Korzekwa, K.R., Crespi, C.L., Gonzalez, F.J., and Gelboin, H.V.: Metabolism of Benzo(a)pyrene by seven cDNA-expressed human cytochromes P450 In. Polycyclic Aromatic Hydrocarbons, Gordon and Breach Science Publishers S.A., Vol. 7, pp 1-9, 1994.
243. Fernandez-Salguero, P., and Gonzalez, F.J.: The CYP2A gene subfamily: Species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5. S123-S128, 1995.
244. Cresteil, T., Marie, S., Kersual, J , Flinois, J.P., and Gonzalez, F.J.: Evidence for the transient expression of a P450 isozyme during the neonatal period in rat. Biochim. Biophys Acta 1208: 111-117, 1994.
245. Rahman, Q., Korzekwa, K.R., Grogan, J., Gonzalez, F.J., and Harris, J.W.. Selective biotransformation of taxol to 6 α -hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543-5546, 1994.
246. Meisma, J., Fernandez-Salguero, P., van Kuilenberg, A., van Gennip, A., and Gonzalez, F.J.: Identification of a mutation in the dihydropyrimidine dehydrogenase gene responsible for thymine uracilurea. DNA and Cell Biol 14:1-6, 1995.
247. Grogan, J., Shou, M., Andrusiak, E.A., Tamura, S., Buters, J.T.M., Gonzalez, F.J., and Korzekwa, K.R.: Cytochrome P450 2A1, 2E1, and 2C9 cDNA-

- expression by insect cell and partial purification using hydrophobic chromatography Biochem Pharmacol 50:1509-1515, 1995
248. Fernandez-Salguero, P., Gonzalez, F.J., and Kimura, S. A thin layer chromatography method for assay of the polymorphically-expressed dihydropyrimidine dehydrogenase activity in human lymphocytes: correlation of activity and protein levels. Biochem Pharmacol 50:1015-1020, 1995.
 249. Crespi, C.L., Penman, B.W., Gonzalez, F.J., Gelboin, H.V. and Langenbach, R.. Genetic toxicology using human cell lines expressing human P450 Biochem Soc Trans 21:1023-1028, 1993.
 250. Meyer, U.A., Gonzalez, F.J., Guengerich, F.P., McManus, M.E., and Okuda, K.: Human cytochromes P450: regulation and functional variability, In: Proceedings of the 12th International Congress of Pharmacology, 1995.
 251. Gonzalez, F.J.: Genetic polymorphism and cancer susceptibility. Cancer Res 55: 710-715, 1995.
 252. Nakajima, T., Elvoara, E., Murayama, N., Gonzalez, F.J., Gelboin, H.V., Raunio, H., Pelkonen, O., Vanio, H. and Aoyama, T.: Styrene metabolism by cDNA expressed human cytochromes P450. Chem Res Toxicol 7: 891-895, 1994.
 253. Ono, S., Hatanaka, T., Hotta, H., Tsutsui, M., Satoh, T., Gonzalez, F.J.: Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143-150, 1995.
 254. Liu, S.Y., and Gonzalez, F.J.: Role of the liver-enriched transcription factor HNF-1 α in expression of the CYP2E1 gene DNA Cell Biol 14: 285-293, 1995
 255. Pineau, T., Fernandez-Salguero, P., Lee, S.S.T., McPhail, T., Ward, J.M., and Gonzalez, F.J.: Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 CYP1A2. Proc Natl Acad Sci, USA 92:5134-5138, 1995.
 256. Hoffman, S.M.G., Fernandez-Salguero, P., Gonzalez, F.J. and Mohrenweiser, H.. Organization of the CYP2A-2B-2F subfamily cluster on human chromosome 19. Mol Evol 41: 894-900, 1995.
 257. Buters, J.T.M., Shou, M., Hardwick, J.P., Korzekwa, K.R., and Gonzalez, F.J.: cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Drug Metab Disp 23:696-701, 1995.
 258. Roberts-Thomson, S.J., McManus, M.E., Tukey, R.T., Gonzalez, F.J., and Holder, G.M.: Metabolism of polycyclic aza-aromatic carcinogens catalyzed by four human cytochromes P450. Cancer Res 55:1052-1059, 1995.
 259. Ono S., Tsutsui, M., Gonzalez, F.J., Satoh, T., Masubuchi, Y., Horie, T., Suzuki, T., and Narimatsu, S.: Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics 5: 97-102, 1995.

260. Crespi, C.L., Steimel, D.T., Penman, B.W., Korzekwa, K.R., Fernandez-Salguero, P., Buters, J.T.M., Gelboin, H.V., Gonzalez, F.J., Idle, J.R. and Daly, A.K. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine at position 374 Pharmacogenetics 4: 234-243, 1995.
261. Fernandez-Salguero, P., Pineau, T., Hilbert, D.M., McPhail, T., Lee, S.S.T., Kimura, S., Nebert, D.W., Rudikoff, S., Ward, J., and Gonzalez, F.J.: Immune system impairment and hepatic fibrosis in mice lacking the aryl-hydrocarbon receptor. Science 268: 722-726, 1995.
262. Lee, S.S.T., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P., Westphal, H., and Gonzalez, F.J.: Targeted disruption of the α -isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022, 1995.
263. Gonzalez, F.J.: Human cytochromes P-450 and their roles in environmentally-based disease, In: R.A. Minear, A.M. Ford, L.L. Needham and N.J. Karch (Eds.) Applications of Molecular Biology in Environmental Chemistry, Lewis Publishers, CRC Press, Boca Raton FL, pp 111-131, 1995.
264. Rettie, A.E., Sheffels, P.R., Korzekwa, K.R., Gonzalez, F.J., Philpot, R.M., and Baille, T.A.: CYP4 isozyme specificity and the relationship between *t*-hydroxylation and terminal desaturation of valproic acid. Biochemistry 34: 7889-7895, 1995.
265. Gonzalez, F.J., and Fernandez-Salguero, P.: Diagnostic analysis and clinical importance of the dihydropyrimidine dehydrogenase polymorphism. Trends Pharmacol Sci 16:325-327, 1995.
266. Fernandez-Salguero, P., Hoffman, S.M.G., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., Pelkonen, O., Huang, J.-D., Evans, W.E., Idle, J.R., and Gonzalez, F.J.: A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles Amer J Hum Genet 57:651-660, 1995.
267. Gonzalez, F.J., Fernandez-Salguero, P., Lee, S.S.T., Pineau, T., and Ward, J.M.: Xenobiotic receptor knockout mice. Tox. Lett. 82/83: 117-121.
268. Lee, S.S.T., and Gonzalez, F.J.: Targeted disruption of the peroxisome proliferator-activated receptor α gene, PPAR α . In: Peroxisomes: Biology and Role in Toxicology and Disease (Reddy, J.J., Suga, T., Mannaerts, G.P., Lazarow, P.B., and Subramani, S., Eds.) Annals N Y Acad Sci., 804:524-529, 1997.
269. Schmalix, W.A., Barrenscheen, M., Landsiedel, R., Janzowski, C., Eisenbrand, G., Gonzalez, F.J., Eliasson, E., Ingelman-Sundberg, M., Perchermeier, M., Weibel, F., Greim, H., and Doehmer, J.: Stable expression of human cytochrome P450 2E1 in V79 Chinese hamster cells. Eur J Pharmac. 293:123-131, 1995.
270. Furuya, H., Gregory, W., Taber, H., Gonzalez, F.J. and Idle, J.R.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulation. Pharmacogenetics 5:389-392, 1995.

271. Gelboin, H.V., Krause, K.W., Goldfarb, I., Buters, J.T.M., Yang, S.K., Gonzalez, F.J., Korzekwa, K.R., and Shou, M.: Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50: 1841-1850, 1995.
272. Thornton-Manning, J., Appleton, M.L., Gonzalez, F.J., and Yost, G.S.: Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes. Correlation of 3-methyleneindolenine formation and protein-binding. J Pharmacol Exp Ther 276: 21-29, 1996.
273. Kimura, S., Hara, Y., Pineau, T., Fernandez-Salguero, P., Fox, C.H., Ward, J.M., and Gonzalez, F.J.: The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 10:60-69, 1996.
274. Nomoto, M., Gonzalez, F.J., Mita, T., Inoue, N., and Kawamura, M.: Analysis of cis-acting regions upstream of the rat Na⁺/K⁺-ATPase $\alpha 1$ subunit gene by in vivo footprinting. Biochem Biophys Acta. 1264: 35-39, 1995.
275. Gonzalez, F.J., Fernandez-Salguero, P., Lee, S.S.T., Pineau, T., and Ward, J.M.: Targeted disruption of the peroxisome proliferator-activated receptor α form (PPAR α) and dioxin-binding Ah-receptor genes. Eur J Drug Metab Pharmacokin 20: 27-18, 1995.
276. Roy, S.K., Korzekwa, K.R., Gonzalez, F.J., Moschel, R.C., and Donlan, M.E.: Human liver oxidative metabolism of O⁶-benzylguanine. Biochem Pharmacol. 50: 1385-1389, 1995.
277. Gonzalez, F.J. and Lee, Y.H.: Mechanisms for constitutive expression of hepatic P450 genes. FASEB J 10: 1112-1117, 1996
278. Buters, J.T.M., Tang, B.K., Pineau, T., Gelboin, H.V., Kimura, S. and Gonzalez, F.J.: Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 6: 291-296, 1996.
279. Pineau, T.P., Sher, T., Hudgens, W.R., Chen, L.C., Liu, L., Gonzalez, F.J., and Samid, D.: Activation of peroxisome proliferator-activated receptor by the nontoxic anticancer agent phenylacetate and its analogs correlates with their cytostatic effect on human tumor cells. Biochem. Pharmacol. 52: 659-667, 1996.
280. Tracy, T.S., Rosenbluth, B.W., Wrighton, S.A., Gonzalez, F.J., and Korzekwa, K.R.: Cytochrome P-450 CYP2C9 and an allelic variant catalyze the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol. 49: 1269-1275, 1995.
281. Gonzalez, F.J.: The use of transgenic and gene knockout in carcinogenesis studies. Molec Carcinog. 16: 63-67, 1996.
282. Lee, S.S.T., Buters, J.T.M., Pineau, T., Fernandez-Salguero, P., and Gonzalez, F.J.: Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol. Chem. 271: 12063-12067, 1996.

- 283 Lee, I J , Jeong, K S , Roberts, B J., Soh, Y , Fernandez-Salguero, P., Gonzalez, F J and Song, B.J.. Transcriptional activation of the cytochrome P450 1A1 gene (CYP1A1) by a synthetic compound, YH439 via an Ah receptor-dependent mechanism Molec Pharmacol 49: 980-988, 1996.
284. Shou, M, Krausz, K W., Gonzalez, F.J. and Gelboin, H V.: Metabolic activation of potent dibenzo[*a,h*]anthracene by cDNA expressed human cytochromes P450 Arch Biochem Biophys 328 201-207, 1996.
- 285 H.V , Goldfarb, I., Krausz, K.W , Grogan, J , Korzekwa, K.R., Gonzalez, F.J., and Shou, M : Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 2E1. Chem Res Toxicol. 9: 1023-1030, 1996.
286. Peters, J.M., Yuan, Y.C., Ram, P.A., Lee, S.S.T., Gonzalez, F.J., and Waxman, D J · Peroxisome proliferator-activated receptor α (PPAR α) mediates gene induction by dehydroepiandrosterone-sulfate. Molec Pharmacol. 50. 67-74, 1996
287. Shou, M., Korzekwa, K R., Krausz, K.W., Buters, J T.M., Grogan, J , Goldfarb, I., Hardwich, J.P., Gonzalez, F.J., and Gelboin, H.V.: The role of nine cDNA-expressed human and four rodent cytochromes P450 in metabolism of the potent carcinogen 7,12-dimethylbenz[*a*]anthracene Molec Carcinog 17: 241-249, 1996.
288. Gonzalez, F.J.: The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility Rep Toxicol 11/2-3: 397-412, 1997.
289. Fernandez-Salguero, P., Hilbert, D.M., Rudikoff, S , Ward, J M., and Gonzalez, F.J.: Aryl-hydrocarbon receptor deficient mice are resistant to TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin) induced toxicity Toxicol Appl Pharmacol 140. 173-179, 1996.
290. Fernandez-Salguero, P. and Gonzalez. F.J.: Targeted disruption of specific cytochromes P450 and xenobiotic receptor genes. Meth. Enzymol. 272: 412-430, 1996.
291. Valentine, J.L., Lee, S S.T , Seaton, M.J., Asgharian, B , Farris, G., Corton, J.C., Gonzalez, F J , and Medinski, M : Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol. Appl Pharmacol. 14: 205-213, 1996.
292. Ryu, D.Y., Levi, P.E., Fernandez-Salguero, P. Gonzalez, F.J. and Hodgson, E.: Piperonyl butoxide and acenaphthylene induce CYP1A2 and CYP2B1 mRNA in Ah receptor knockout mouse liver. Molec Pharmacol. 50: 443-447, 1996.
293. Wei, X , McLeod, H.L., Gonzalez, F J, And Fernandez-Salguero, P.: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity J Clin Invest. 98:610-615, 1996.
294. FitzGerald, C.T., Fernandez-Salguero, P., Gonzalez, F.J., Nebert, D W., and Puga, A.: Differential regulation of mouse Ah receptor gene expression in cell lines of different tissue origins. Arch Biochem. Biophys 333: 170-178, 1996.
295. Shou, M., Krausz, K.W., Gonzalez, F.G., and Gelboin, H.V.: Metabolic activation of the potent carcinogen dibenzo[*a,l*]pyrene by human recombinant

cytochromes P450, lung and liver microsomes Carcinogenesis 17 2429-2433, 1996.

296. Gonzalez, F J : Overview of experimental approaches for study of drug metabolism and drug-drug interactions. in Drug Interactions: Scientific and Regulatory Perspectives, (A.P Li, Ed) Adv Pharmacol 43: 255-277, 1997
297. Liu, C., Zhuo, X , Gonzalez, F.J. and Ding, X. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: Role in metabolic activation of nasal toxicants. Molec Pharmacol. 50:781-788, 1996
298. Chen, L.P., Buters, J.T.M., Tamura, S., Hardwick, J.P., Penman, B W., Gonzalez, F.J., and Crespi, C L.: Coexpression of CYP2A6 and NADPH-P450 oxidoreductase in the baculovirus system. Drug Metab Disp. 25:399-405, 1997.
299. Devchand, P.R., Keller, H., Peters, J M., Vazquez, M., and Gonzalez, F J.: The PPAR α -leukotriene pathway to inflammation control. Nature 384 39-43, 1996.
300. Daly, A.K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W.E., Gonzalez, F.J, Huang, J.D , Idle, J.R., Ingleman-Sundberg, M., Ishizaki, T., Jacqz-Agarain, E., Meyer, U.A., Nebert, D W., Steen, V.M., Wolf, C.R., and Zanger, U.M.. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6 193-202, 1996.
301. Hansen, A.J., Lee, Y H., Gonzalez, F.J. and Mackenzie, P.I.: HNF1 α activates the rat UDP glucuronosyltransferase UGT2B1 gene promoter. DNA Cell Biol. 16. 207-214, 1997.
302. Yokoi, Y., Kosaka, Y., Chida, M., Chiba, K., Nakamura, H., Ishizaki, T., Kinoshita, M , Sato, K., Gonzalez, F J., and Kama T.: A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 6: 395-401, 1996.
303. Motojima, K., Peters, J.M. and Gonzalez, F.J.: PPAR α mediates peroxisome proliferator-induced transcriptional repression of non-peroxisomal gene expression in mouse. Biochem. Biophys. Res. Com. 230: 155-158, 1997.
304. Shou, M , Korzekwa, K.R., Brooks, E.N., Krause, K.W., Gonzalez, F.J. and Gelboin, H.V.: Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone Carcinogenesis 18. 207-214, 1997.
305. Ono. S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F.J., and Tsutsui, M.: Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26: 681-693, 1996.
306. Gonzalez, F.J.: The role of peroxisome proliferator activated receptor α in peroxisome proliferation: physiological homeostasis and chemical carcinogenesis. Adv. Exp Med Biol. 422:109-125, 1997.
307. Nakagawa, T., Sawada, T., Gonzalez, F.J., Yokoi, T., and Kamataki, T.: Stable expression of human CYP2E1 in Chinese hamster cells:high sensitivity to N,N,-dimethylnitrosamine in cytotoxicity testing. Mutat. Res. 360: 181-186, 1996.

308. Shou, M., Gonzalez, F.J., and Gelboin, H.V.: Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2 and epoxide hydrolase Biochemistry 35: 15807-15812, 1996.
309. Tracy, T.S., Marra, C., Wrighton, S.A., Gonzalez, F.J. and Korzekwa, K.R. Studies of flurbiprofen 4'-hydroxylation: additional evidence suggesting the sole involvement of cytochrome P450 2C9 Biochem Pharmacol. 52: 1305-1309, 1996.
310. Gonzalez, F.J.: Recent update on PPAR α -null mice Biochimie 79: 139-144, 1997.
311. Code, E.L., Crespi, C.L., Penman, B.W., Gonzalez, F.J., Chang, T.K.H., and Waxman, D.J.: Human cytochrome P450 2B6: interindividual hepatic expression, substrate specificity and role in procarcinogen activation. Drug Metab Disp 25: 985-993, 1997.
312. Fernandez-Salguero, P.M., Sapone, A., Wei, X., Holt, J.R., Idle, J.R., and Gonzalez, F.J.: Thymine-uraciluria and lack of dihydropyrimidine dehydrogenase activity caused by a common splice mutation Pharmacogenetics 7: 161-163, 1997.
313. Gonzalez, F.J., Fernandez-Salguero, P., and Ward, J.M.: The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD Toxicol Sci 21: 273-277, 1996.
314. Ono, S., Hatanaka, T., Miyazawa, S., Tsutsui, M., Aoyama, T., Gonzalez, F.J., and Satoh, T.: Human liver microsomal diazepam metabolism using cDNA-expressed cytochromes P450s: role of CYP2B6, 2C19 and 3A subfamily Xenobiotica 26: 1155-1166, 1996.
315. Lee, Y.H., Williams, S.C., Baer, M., Sterneck, E., Gonzalez, F.J. and Johnson, P.F.: Ability of C/EBP β but not C/EBP α to synergize with an Sp1 protein is specified by the leucine zipper and activation domain Mol Cell Biol. 17: 2038-2047, 1997.
316. Mihara, K., Otani, K., Suzuki, A., Yasui, N., Nakano, H., Meng, X., Ohkubo, T., Osana, T., Kaneko, S., Tsuchida, H., Sugawara, K., and Gonzalez, F.J.: Relationship between the CYP2D6 genotype and the steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. J. Neuropsy. 133: 95-98, 1997.
317. Lee, Y.H., Sauer, B., Johnson, P.F., and Gonzalez, F.J.: Disruption of the *c/ebp α* gene in adult mice. Mol Cell Biol. 17: 6014-6022, 1997.
318. Rosenbaum, K., Schaffrath, B., Hagen, W.R., Jahnke, K., Gonzalez, F.J., Cook, P.F., and Schnackerz, K.D.: Purification, characterization and kinetics of recombinant Escherichia coli dihydropyrimidine dehydrogenase. Prot Expr Purif. 10: 185-191, 1997.
319. Chittum, H.S., Beck, H.J., Diamand, A.M., Fernandez-Salguero, P., Gonzalez, F.J., Ohama, T., Hatfield, D.J., Kuehn, M., and Lee, B.J.: Selenocysteine (Sec) tRNA levels and selenium-dependent glutathione peroxidase activity in mouse cells heterozygous for the Sec tRNA^{[Ser]Sec} gene Biochemistry 36: 8634-8639, 1997.

320. Ridge, S.A., Brown, O., McMurry, J., Fernandez-Salguero, P.M., Evans, W.E., and Gonzalez, F.J., and McCleod, H.L.: Mutations at codon 974 of the DPYD gene are a rare event Brit J Cancer 75: 178-179, 1997.
321. Yamamoto, Y., Tasaki, T., Nakamura, A., Iwata, H., Kazusaka, A., Gonzalez, F.J. and Fujita, S.: Molecular basis of the Dark Agouti rat drug oxidation polymorphism. involvement of CYP2D1 and CYP2D2. Pharmacogenetics 8: 73-82, 1998.
322. Krause, K., Yang, T.J., Gonzalez, F.J. and Gelboin, H.V.: Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Biochem Pharmacol. 54: 15-17, 1997.
323. Andreola, F., Fernandez-Salguero, P.M., Chiantore, M.V., Petkovich, M.P., Gonzalez, F.J., and DeLuca, L.M.: Aryl hydrocarbon receptor deficient mice (AHR^{-/-}) exhibit accumulation of liver retinoic acid, retinol and retinyl palmitate and altered retinoic acid metabolism. Cancer Res. 57: 2835-2838, 1997.
324. Ren, R., Thelen, A.P., Peters, J.M., Gonzalez, F.J., and Jump, D.B.: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require PPAR α . J Biol Chem. 272: 26827-26832, 1997.
325. Ward, J.M., Peters, J.M., Perella, C.M. and Gonzalez, F.J.: Receptor and non-receptor mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor α -null mice. Tox Pathol. 26: 240-246, 1998.
326. Peters, J.M., Hennuyer, N., Staels, B., Fievet, C., Gonzalez, F.J., and Auwerx, J.: Alterations in lipoprotein metabolism in PPAR α -deficient mice. J Biol Chem. 272: 27307-27312, 1997.
327. Fernandez-Salguero, P., Ward, J., Sundberg, J.P., and Gonzalez, F.J.: Lesions of aryl-hydrocarbon receptor-deficient mice Vet Pathol. 34: 605-614, 1997.
328. Mace, K., Aguilar, F., Wang, J.S., Vautravers, P., Gomez-Lechon, M., Gonzalez, F.J., Groopman, J., Harris, C.C. and Pfeifer, A.M.A.: Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18: 1291-1297, 1997.
329. Peters, J.M., Cattley, R.C. and Gonzalez, F.J.: Role of PPAR α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator WY-14,643. Carcinogenesis 18: 101-105, 1997.
330. Hansen, A.J., Lee, Y.H., Sterneck, E., Gonzalez, F.J. and Mackenzie, P.I.: C/EBP α is a regulator of the UDP-glucuronosyltransferase UGT2B1 gene. Mol. Pharmacol. 53: 1027-1033, 1998.
331. Nakajima, T., Wang, R.S., Elovaara, E., Gonzalez, F.J., Gelboin, H.V., Raunio, H., Pelkonen, O., Vainio, H., and Aoyama, T.: Toluene Metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem. Pharm. 53: 271-277, 1997.
332. Radjendirane, V., Joseph, P., Lee, Y.H., Kimura, S., Klein-Szanto, A.J.P., Gonzalez, F.J., and Jaiswal, A.K.: Disruption of the DT diaphorase (NQO1) gene

- in mice leads to increased menadione toxicity J Biol Chem 273: 7382-7389, 1998.
333. Lee, Y.H., Sauer, B., and Gonzalez, F.J. Laron dwarfism and non-insulin-dependent diabetes in the *Hnf-1 α* knockout mouse Mol Cell Biol 18: 3059-3068, 1998.
334. Gelboin, H.V., Krausz, K.W., Shou, M., Gonzalez, F.J., and Yang, T.J. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific tissue metabolism. Pharmacogenetics 7: 469-477, 1997.
335. Aoyama, T., Peters, J.M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T. and Gonzalez, F.J.. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPAR α) J Biol Chem 273: 5678-5684, 1998.
336. Zaher, H., Buters, J.T.M., Ward, J.M., Bruno, M.K., Lucas, A.M., Stern, S.T., Cohen, S.D., and Gonzalez, F.J.: Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Tox Appl Pharmacol 152:193-199, 1998.
337. Peters, J.M., Taubeneck, M.W., Keen, C.L., and Gonzalez, F.J.: D₁ (ethylhexyl) phthalate induces a functional zinc deficiency during pregnancy and teratogenesis that is independent of peroxisome proliferator-activated receptor α . Teratology 56: 311-316, 1997.
338. Zaher, H., Fernandez-Salguero, P.M., Letterio, J., Sheikh, M.S., Roberts, A.B., Fornace, A.J. and Gonzalez, F.J.: Increased expression of transforming growth factor β and apoptosis in the livers of aryl hydrocarbon receptor-deficient mice. Molec Pharmacol 54: 313-321, 1998.
339. Wei, X., Elizondo, G., Sapone, A., McLeod, H.L., Raunio, H., Fernandez-Salguero, P., and Gonzalez, F.J.: Characterization of the human dihydropyridine dehydrogenase gene: gene structure and genetic polymorphism. Genomics 51:391-400, 1998.
340. Ridge, S.A., Sludden, J., Brown, O., Robertson, L., Wei, X., Sapone, A., Fernandez-Salguero, P.M., Gonzalez, F.J., Vreken, P., van Kuilenburg, A.B.P., van Gennip, A.H., McLeod, H.L.: Dihydropyridine dehydrogenase pharmacogenetics in Caucasian subjects. 46: Br J Clin Pharmacol 46: 151-156, 1998.
341. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., and Latruffe, N.: Expression of the fatty acid transporter genes are regulated by PPAR α and γ activators in a tissue and inducer-specific manner. J. Biol. Chem 273: 16710-16714, 1998.
342. Chen, H.C., Gonzalez, F.J., Shou, M., and Chung, F.L.: 2,3-Epoxy-4-hydroxynonanal, a potential lipid peroxidation product for ewtheno adduct formation, is not a substrate of human epoxide hydrolase hydrolysis. Carcinogenesis 19: 939-943, 1998.

- 343 Yang, T.J., Shou, M., Korzekwa, K.K., Gonzalez, F.J., Gelboin, H.V. and Yang, S.K.: Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 55: 889-896, 1998.
- 344 McLeod, H.L., Sludden, J., Murray, G.I., Keenan, R.A., Davidson, A.I., Park, K., Koruth, M., and Cassidy, J.: Characterization of dihydropyridine dehydrogenase in human colorectal tumours Brit J Cancer 77: 461-465, 1998.
345. Ridge, S.A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F.J., Cassidy, J., and McLeod, H.L.: Dihydropyridine dehydrogenase pharmacogenetics in patients with colorectal cancer. Brit J Cancer 77: 497-500, 1998.
346. Djoudi, F., Weinheimer, C.J., Saffitz, J.E., Saffitz, J.E., Pitchford, C., Bastin, J., Gonzalez, F.J., and Kelly, D.P.: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α -deficient mice. J Clin Invest. 102: 1083-1091, 1998.
347. Korzekwa, K.R., Krishnamachary, N., Shou, M., Ogas, A., Paris, R.A., Rettie, A.E., Gonzalez, F.J., and Tracy, T.S.: Evaluation of atypical cytochrome P450 kinetics with two-substrate-models. evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 24: 4137-4147, 1998.
348. McLeod, H.L., Collie-Duguid, E.S.R., Vreken, P., Wei, X., Diasio, R.B., Fernandez-Salguero, P., van Kuilenburg, A.B.P., van Gennip, A.H., and Gonzalez, F.J.: Nomenclature for human DPYD alleles. Pharmacogenetics 8:455-459, 1998.
349. Fischer, M.B., Gonzalez, F.J., Rettie, A.E.: Human CYP2E1 and CYP2A6 mediate the formation of the hepatotoxin 4-ene valproic acid. J Pharmacol Exp Ther. (In press).
350. Peters, J.M., Narotsky, M.G., Elizondo, G., Fernandez-Salguero, P.M., Gonzalez, F.J. and Abbott, B.D.: Amelioration of TCDD-induced teratogenesis in aryl hydrocarbon receptor (AhR)-null mice. J Toxicol Sci. 47: 86-92, 1999.
351. Peters J.M., Aoyama, T., Cattley, R.C., Usuda, N., Hashimoto, T., Gonzalez, F.J.: Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver. Carcinogenesis 19: 1989-1994, 1998.
352. Djoudi, F., Weinheimer, C.J., Saffitz, J.E., Saffitz, J.E., Pitchford, C., Bastin, J., Gonzalez, F.J., and Kelly, D.P.: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α -deficient mice. J Clin Invest. 102: 1083-1091, 1998.
353. Gonzalez, F.J., Peters, J.M., and Cattley, R.C.: Mechanism of action of the non-genotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor α (PPAR α). J Natl. Cancer Inst. 90: 1702-1709, 1998.
354. Yang, T.J., Krausz, K.W., Shou, M., Yang, S.K., Buters, J.T.M., Gonzalez, F.J., and Gelboin, H.V.: Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 55: 1633-1640.

355. Suzuki, A., Kushida, H., Iwata, H., Watanabe, M., Nohmi, T., Fujita, K., Gonzalez, F.J., and Kamataki, T.: Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines. Cancer Res 58 1833-1838, 1998.
356. Saarikoski, S.T., Husgafvel-Pursainen, K., Hirvonen, A., Vanio, H., Gonzalez, F.J., and Antila, S.: Localization of CYP1A1 mRNA in human lung by in situ hybridization. comparison with immunohistochemical findings Int J Cancer, 77. 33-39, 1998.
357. Yang, T.J., Krausz, K.W., Gonzalez, F.J., and Gelboin, H.V.: Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics 8 375-382, 1998
358. Shou, M., Martinet, M., Korzekwa, K.R., Krausz, K.W., Gonzalez, F.J., and Gelboin, H.V.: Metabolism of taxotere (RP56976) and its derivatives (RPR10452 and RP70617) role of cytochromes P450 3A3, 3A4, and 3A5 isozymes and their metabolic contribution in human liver. Pharmacogenetics 8. 391-401, 1998
359. Alexander, D.L., Ganem, L.G., Fernandez-Salguero, P., Gonzalez, F.J., and Jefcoate, C.R.: Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci. 111.3311-3322, 1998.
360. Gonzalez, F.J., and Fernandez-Salguero, P.: The aryl hydrocarbon receptor: Studies using the AHR-null mice. Drug Metab Disp. 26: 1194-1198, 1998. ✓
361. Yang, T.J., Shou, M., Korzekwa, K.R., Gonzalez, F.J., Gelboin, F.J. and Yang, S.K.: Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol. 15: 889-896, 1998.
362. Morgan, E.T., Sewer, M.B., Iber, H., Gonzalez, F.J., Yue-Hue, L., Tukey, R.H., Okino, S., Vu, T., Chen, Y.H., Sindhu, J.S., and Omiecinski, C.J.: Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Disp. 26: 1232-1240, 1998. ✓
363. Nagata, K., Ogino, M., Shimada, M., Miyata, M., Gonzalez, F.J. and Yamazoe, Y.: Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6βB). Arch Biochem Biophys. 362: 242-253, 1999.
364. Buters, J.T.M., Sakai, S., Pineau, T., Alexander, D.L., Savas, U., Doehmer, J., Ward, J.M., Jefcoate, C.R. and Gonzalez, F.J.: The cytochrome P450 CYP1B1-null mouse is resistant to dimethylbenz[*a*]anthracene-induced lymphomas. Proc Natl. Acad. Sci. USA 96: 1977-1982, 1999.
365. Chen, S.C., Wang, Z., Xu, G., Zhou, L., Vennerstrom, J.L., Gonzalez, F.J., Gelboin, H.V. and Mirvish, S.S.: Depentylation of [3H-pentyl]-methyl-n-Amylnitrisamine by rat esophageal and liver microsomes and by rat and human cytochrome P450 isoforms. Cancer Res. 59: 91-98, 1999.
366. Ghanayem, B.I., Sanders, J.M., Chanas, B., Burka, L.T., and Gonzalez, F.J.: Role of cytochrome P-450 2E1 in methacrylonitrile metabolism and disposition. J. Pharmacol Exp Ther 289: 1054-1059, 1999.

- 367 Kockx, M., Gervois, P.P., Poulain, P., Derudas, B., Peters, J.M., Gonzalez, F.J., Prineen, H.M.G., Kooistra, T., and Staels, B.: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor Blood 93: 2991-2998, 1999
368. Tracy, T.S., Korzekwa, K.R., Gonzalez, F.J., and Warner, I.W.: Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47: 545-552, 1999.
369. Gelboin, H.V., Krausz, K.W., Shou, M., Gonzalez, F.J. and Yang, T.J.: Inhibitory monoclonal antibodies define the role of cytochromes P450 in human tissue: the polymorphically-expressed CYP2D6 as a paradigm. Pharmacogenetics (In press).
370. Peters, J.M., Morishima, H., Ward, J.M., Coakley, C.J., Kimura, S., and Gonzalez, F.J.: Role of CYP1A2 in the toxicity and toxicity carcinogenicity of long-term phenacetin feeding in mice. J Toxicol Sci. (In press).
371. Gonzalez, F.J.: The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption. Toxicol Lett 102-103: 161-166, 1999. ✓
372. Hong, J.Y., Wang, Y.Y., Bondoc, F.Y., Yang, C.S., Gonzalez, F.J., Pan, Z., Cokonis, C.D., Hu, W.Y., Bao Z.: Metabolism of methyl tert-butyl ether and other gasoline ethers in mouse liver microsomes lacking cytochrome P450 2E1. Toxicol Lett. 105: 83-88, 1999
373. Koskela, S., Hakkola, J., Hukkanene, J., Pelkonen, O., Sorri, M., Saranen, A., Antila, S., Fernandez-Salguero, P.M., Gonzalez, F.J., and Raunio, H.: Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharm. (In press).
374. Gonzalez, F.J.: Pharmacogenetics: polymorphisms in xenobiotic metabolisms. In: Molecular and Applied Aspects of Oxidative Drug Metabolizing Enzymes, NATO ASI Series Vol. 303, (E. Arinc, J.B. Schenkman and E. Hodgson, Eds), Kluwer Academic/Plenum Publishers, New York, pp 91- 110, 1999.
375. Buters, J.T.M., Doehmer, J., and Gonzalez, F.J.: Cytochrome P450-null mice, Drug Metab Rev. 31: 437-447, 1999. ✓
376. Hashimoto, T., Fujita, T., Usuda, N., Cook, W., Qi, C., Peters, J.M., Gonzalez, F.J., Yeldandi, A.V., Rao, M.S., and Reddy, J.R.: Peroxisomal and mitochondrial fatty acid β -oxidation in mice nullizygous for both PPAR α and peroxisomal fatty acyl-CoA oxidase: genotype correlation with fatty liver phenotype. J Biol Chem. 274: 19228-19236, 1999
377. Sai, Y., Yang, T.J., Krausz, K.W., Gonzalez, F.J., and Gelboin, H.V.: An inhibitory monoclonal antibody to human P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9: 229-237, 1999.
378. Koskela, S., Hakkola, J., Hukkanene, J., Pelkonen, O., Sorri, M., Saranen, A., Antila, S., Fernandez-Salguero, P.M., Gonzalez, F.J., and Raunio, H.:

Expression of CYP2A genes in human liver and extrahepatic tissues
Biochem Pharm (In press).

379. Kersten, S., Seydoux, J., Gonzalez, F.J., Desvergne, B., and Wahli, W.: Peroxisome proliferator-activated receptor α is essential for mediating the transcriptional response to fasting J Clin Invest. 103. 1489-1498, 1999.
380. Barclay, T.B., Peters, J.M., Sewer, M.B., Ferrari, L., Gonzalez, F.J., and Morgan, E.: Modulation of cytochrome P450 gene expression in endotoxemic mice is tissue-specific and PPAR α -dependent. J Pharmacol Exp Ther. 290: 1250-1257, 1999.
381. Hill, M.R., Clarke, S., Rodgers, K., Hoebing, B., Peters, J.M., Gonzalez, F.J., and Gimble, J.M.: Effect of PPAR α activators on TNF expression in mice during endotoxemia. Infection and Immunity 67: 3488-3493, 1999.
382. Bondoc, F.Y., Bao, Z., Hu, W.Y., Gonzalez, F.J., Wang, Y., Yang, C.S., and Hong, J.Y.: Acetone catabolism by cytochrome P450 2E1. studies with CYP2E1-null mice. Biochem. Pharmacol. 58. 461-463, 1999.
383. Djouadi, F., Brandt, J.M., Weinheimer, C.J., Leone, B.S., Gonzalez, F.J., and Kelly, D.P.: The role of the peroxisome proliferator-activated receptor α (PPAR α) in the control of cardiac lipid metabolism. *In: Prostaglandins. Leukotrienes and Essential Fatty Acids*. (In press).
384. Miyata, M., Kudo, J., Lee, Y.H., Yang, T.J., Gelboin, H.V., Fernandez-Salguero, P., Kimura, S., and Gonzalez, F.J.: Targeted disruption of the microsomal epoxide hydrolase gene. microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12,-dimethylbenz[a]anthracene J Biol Chem. 274. 23963-23968, 1999.
385. Wu, X., Peters, J.M., Gonzalez, F.J., Prasad, H.S., Rohrer, M.D., and Gimble, J.M.: The frequency of stromal lineage colony forming units in the bone marrow of peroxisome proliferator-activated receptor α null mice Bone (In press).
386. Gonzalez, F.J., and Kimura, S.: Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis. Cancer Lett (In press).
387. Kimura, S., Kawabe, M., Ward, J.M., Morishima, H., Kadlubar, F.F., Hammonds, G.J., Fernandez-Salguero, P., and Gonzalez, F.J.: CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl hepatocarcinogenesis in mice. Carcinogenesis (In press).
388. Gelboin, H.V., Krausz, K.W., Gonzalez, F.J., and Yang, T.J.: Deciphering microsomes with inhibitory monoclonal antibodies that define the metabolic role of ten human cytochromes P450: a new avenue of drug discovery. Trends Pharmacol. Sci. (In press).
389. Corton, J.C., Lapinskas, P.J., and Gonzalez, F.J.: Central role of PPAR α in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res (In press).
390. Heidel, S.M., Holston, K., Buters, J.T.M., Gonzalez, F.J., Jefcoate, C.R., Czuprynski, C.J.: Bone marrow stromal cell cytochrome P4501B1 is required for

preB cell apoptosis induced by 7,12-dimethylbenz[a]anthracene Molec Pharmacol (In press).

BENJAMIN A. JACKSON, Ph.D.
3116 BIRCHTREE LANE
SILVER SPRING, MD 20906
(301) 871-6821

EDUCATION -

- 1978 MBA, Management, Fairleigh Dickinson University
- 1957 Ph.D., Biology, New York University
- 1951 M S , Biology, Rensselaer Polytechnic Institute
- 1950 A.B., Mathematics and Science, New York State College for Teachers at Albany (presently the State University of New York at Albany)

CERTIFICATION

Fellow, Academy of Toxicological Sciences

EXPERIENCE

MeSH Indexer, Information Ventures (1995- present). Indexed bio-medical publications for the National Library of Medicine's Subject Headings (MeSH) Indexing Contract. Other short term indexing jobs for Herner and Co. and for Aspen Systems Corp.

Private Consultant, Regulatory Toxicology (1992- present) Evaluated protocols and draft final reports, performed presubmission review of carcinogenesis bioassays, prepared weight-of-the-evidence position paper on organ site carcinogenicity, developed preclinical program for medical device, monitored ongoing studies for sponsors and prepared report on acute toxicity study for biotechnology product. Participated in external peer review of EPA's human health risk assessment on a pesticide for the Integrated Risk Information System (IRIS).

Provided consultative advice to special committee on safety factors for reproductive effects for FDA's Center for Food Safety and Applied Nutrition.

Project Manager for Priority-Based Food Additive (PAFA) Project. (1992-1997)
Provide management support and scientific consultation for contractor maintaining FDA's food additive data base.

Senior Science Advisor, Health Sciences. Environ Corporation, Arlington, VA (1990-1992). Provided project management and expertise in toxicology for projects in food toxicology, carcinogenesis bioassays, risk assessment, developmental toxicity, litigation support, and toxicologic pathology.

Director, Division of Pathology, Office of Toxicological Sciences, Center for Food Safety and Applied Nutrition, Food and Drug Administration (1985-1990). Provided administrative direction and scientific leadership for pathology support of in-house laboratory investigations for Divisions of Nutrition, Toxicology and Microbiology, and review and evaluation of pathology data submitted to Agency in support of food and color additive petitions. Served on CFSAN's Cancer Assessment and Quantitative Risk Assessment Committees. Director of Risk Assessment Program. Member of Center's Operations Committee for Beltsville Mod I. Facility. Contributed to portions of the revised Redbook (Redbook II, "Toxicological principles for the Safety Assessment of Direct food Additives and Color Additives used in Food").

Chief, Color and Cosmetics Evaluation Branch, Bureau of Foods, FDA (1980-1985). Supervised and managed interdisciplinary reviews of chronic studies of provisionally listed color additives and toxicity information on cosmetic ingredients.

Team Leader, Antiparasitics, Food Animal Additives Evaluation Branch, Bureau of Foods, FDA (1978-1980). Supervised reviews of human safety evaluations and setting of tolerance levels for animals drugs (antiparasitics, pharmacologically-active agents) and their metabolites in edible tissues of farm animals.

Manager, Reproductive Safety and Experimental Mutagenesis, Toxicology Section, Lederle Laboratories, American Cyanamid Company, Pearl River, NY. (1976-1978). Corporate expert on reproductive safety and mutagenesis. Approved summary information and provided consultative advice on protocol design and interpretation of reproductive and developmental studies and mutagenesis data on candidate drugs, marketed drugs and other chemicals for the United States and overseas.

Group Leader, Reproductive Safety and Teratology, Toxicology Section, Lederle Laboratories, Pearl River, NY. (1969-1976). Supervised in house and monitored outside contract studies on reproductive safety and teratology of candidate drugs. Developed information on reproductive safety of candidate drugs and marketed products for submission to regulatory agencies worldwide. Designed studies, reviewed and evaluated and approved results of reproductive safety testing done in Great Britain, France, Italy and Japan for submission to regulatory agencies. Represented company in matters concerning reproductive safety at meetings with regulatory agencies (FDA, CSM).

Electron Microscopist, Sterling-Winthrop Research Institute, Rensselaer, NY. (1967-1969). Carried out studies of effects of candidate drugs on ultrastructure of liver and eye. Collaborated with Institute Staff on studies of basement membrane of glomeruli in experimentally-induced diabetes; ultrastructural liver cell changes in schistosomiasis infestation and following therapy of this disease; electron microscopic study of atherosclerosis in miniature swine, ultrastructural features of platelet aggregation, and electron microscopy of milk of magnesia particles.